# Research reports

7 reports in full, oldest first.

## Contents

1. [US healthcare data infrastructure: gaps and opportunities in claims clearinghouses, EDI, EHR interoperability and prior authorization](#us-healthcare-data-infrastructure-gaps-and-opportunities-in-claims-clearinghouses-edi-ehr-interoperability-and-prior-authorization) — 2026-08-09 15:19 UTC
2. [Unsolved Technical Problems in US Healthcare IT Infrastructure](#unsolved-technical-problems-in-us-healthcare-it-infrastructure) — 2026-08-09 15:39 UTC
3. [US Healthcare Interoperability Vendors and Funding Landscape](#us-healthcare-interoperability-vendors-and-funding-landscape) — 2026-08-09 15:52 UTC
4. [Documented failures and unsolved problems in healthcare AI](#documented-failures-and-unsolved-problems-in-healthcare-ai) — 2026-08-09 16:05 UTC
5. [LLMs and AI for medical terminology mapping and normalization](#llms-and-ai-for-medical-terminology-mapping-and-normalization) — 2026-08-09 16:18 UTC
6. [FDA real-world performance monitoring and drift detection for AI-enabled medical devices (Sept 2025 Digital Health Center of Excellence RFI, PCCP guidance, postmarket surveillance)](#fda-real-world-performance-monitoring-and-drift-detection-for-ai-enabled-medical-devices-sept-2025-digital-health-center-of-excellence-rfi-pccp-guidance-postmarket-surveillance) — 2026-08-09 16:39 UTC
7. [NVIDIA Corporation (NVDA)](#nvidia-corporation-nvda) — 2026-08-16 09:02 UTC

---

# Research report: US healthcare data infrastructure: gaps and opportunities in claims clearinghouses, EDI, EHR interoperability and prior authorization

**Request:** US healthcare data infrastructure: gaps and opportunities in claims clearinghouses, EDI, EHR interoperability and prior authorization  
**Generated:** 2026-08-09 15:19 UTC

## Executive summary

US healthcare data infrastructure relies on clearinghouses to convert provider claims into standardized EDI 837/835 formats, perform pre‑submission validation, and support prior‑authorization checks. The CMS Interoperability and Prior Authorization Final Rule (CMS‑0057‑F), issued January 17 2024, mandates FHIR‑based APIs for impacted payers (Medicare Advantage, Medicaid, CHIP, QHP issuers) and introduces decision‑timeframes, denial‑transparency, and a MIPS electronic prior‑authorization measure, with staggered compliance dates (operational provisions effective 2026, API requirements generally by Jan 1 2027). Critics note that current clearinghouse/EDI solutions remain costly, fragmented, and have not eliminated prior‑authorization delays, imposing significant administrative burden on providers. Emerging opportunities include AI‑driven prior‑authorization automation, hyper‑automation of EHR workflows, and the integration of FHIR standards with AI to enable real‑time approvals, with the AI‑PA market projected to grow from $1.47 billion in 2025 to $10.31 billion by 2035. Together, regulatory mandates and technological advances aim to reduce administrative costs, improve claim‑submission efficiency, and generate substantial savings across the system.

## Mechanism and standards of claims clearinghouses, EDI, and prior authorization

Healthcare clearinghouses act as intermediaries that convert provider-generated claims into standardized EDI 837 format, validate them against X12 standards and payer-specific rules, and securely transmit them to payers. After adjudication, they receive EDI 835 remittance advice, facilitate payment posting, and offer denial management and analytics. Many clearinghouses also handle eligibility and authorization transactions, performing pre-submission checks for prior authorization requirements to reduce denials.

**Clearinghouses convert provider-generated claims into EDI 837 format and validate the structure against ANSI X12 standards before transmission to payers.**

Providers create claims in EHR or practice management systems; the clearinghouse translates the data into the standard electronic data interchange format (EDI 837 for professional claims, EDI 837I for institutional claims), validates that all required fields are present and correctly formatted, and ensures compliance with X12 standards so that payer systems can process the claim efficiently.

- Evidence: [How Medical Billing Clearinghouses Work? Best Guide](https://www.medibillrcm.com/blog/how-medical-billing-clearinghouses-work/)

**Clearinghouses perform automated claim scrubbing using rules engines to detect errors such as missing patient/insurance data, mismatched ICD-10 or CPT codes, payer-specific rule violations (e.g., LCD/NCD policies), and NPI mismatches, flagging issues for correction before submission.**

The rules engine validates claims against payer-specific billing rules and CMS guidelines; claims that fail these checks are returned to the provider with real-time notifications, allowing staff to correct and resubmit. This pre-submission validation reduces denials and improves clean claim rates.

- Evidence: [How Medical Billing Clearinghouses Work? Best Guide](https://www.medibillrcm.com/blog/how-medical-billing-clearinghouses-work/)

**After payer adjudication, clearinghouses receive EDI 835 remittance advice containing payment details, adjustment codes, and denial reason codes, which they reconcile with provider records to post payments and trigger follow-up workflows for denials.**

The payer sends an EDI 835 file (ERA) that includes payment amounts, patient responsibility, adjustment codes (e.g., contractual write-offs), and denial reason codes (e.g., CO-16 for missing information). Clearinghouses automate payment posting, update accounts receivable, and provide denial management services such as root-cause tagging and automated resubmission workflows, which can increase clean claim rates by 15–30%.

- Evidence: [How Medical Billing Clearinghouses Work? Best Guide](https://www.medibillrcm.com/blog/how-medical-billing-clearinghouses-work/)

**Clearinghouses support prior authorization by processing eligibility and authorization transactions alongside claims, performing pre-submission checks for missing authorizations to reduce denials due to lack of prior approval.**

Clearinghouses provide national-scale transaction connectivity for eligibility, authorization, claims, and payments; they can verify that services requiring prior approval have the necessary authorization before claim submission. Some clearinghouses use AI-powered scrubbing to detect missing authorizations pre-submission, as demonstrated by a cardiology group that reduced denials from 22% to 7% in four months using such capabilities.

- Evidence: [EDI Clearinghouse | Healthcare Solutions](https://www.availity.com/clearinghouse-and-trading-partner-network/)
- Evidence: [How Medical Billing Clearinghouses Work? Best Guide](https://www.medibillrcm.com/blog/how-medical-billing-clearinghouses-work/)
- Evidence: [Top 10 Clearinghouses in Medical Billing (2026)](https://claimmaxrcm.com/top-10-clearinghouses-in-medical-billing-2026-pricing-pros-cons-compared/)


## Current state: gaps, challenges, and regulatory impact (CMS-0057-F)

The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), released January 17, 2024, addresses longstanding gaps in U.S. healthcare data infrastructure—such as fragmented health information exchange, manual prior‑authorization workflows, and administrative burden—by mandating FHIR‑based APIs for payers and imposing new operational requirements on prior authorization. The rule sets staggered compliance dates (operational provisions effective 2026, API requirements generally by 2027), introduces decision‑timeframe and denial‑transparency standards, adds a MIPS electronic prior‑authorization measure, and provides enforcement discretion for FHIR‑only implementations, collectively seeking to streamline data exchange and reduce costs for patients, providers, and payers.

**CMS released the Interoperability and Prior Authorization Final Rule (CMS-0057-F) on January 17, 2024, applying to Medicare Advantage, Medicaid, CHIP, and QHP issuers on the Federally Facilitated Exchanges.**

The rule impacts Medicare Advantage organizations, state Medicaid and CHIP Fee-for-Service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the Federally Facilitated Exchanges (collectively “impacted payers”). It builds on the 2020 CMS Interoperability and Patient Access final rule (CMS-9115-F) and adds provisions to improve health information exchange and prior authorization processes.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)
- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)

**Impacted payers must implement and maintain four FHIR‑based APIs (Patient Access, Provider Access, Payer-to-Payer, Prior Authorization) with API compliance required generally by January 1, 2027.**

The Patient Access API must include prior‑authorization information (excluding drugs) by Jan 1, 2027. The Provider Access API and Payer-to-Payer API must share claims, encounter data, USCDI, and prior‑authorization data by Jan 1, 2027. The Prior Authorization API must support request/response and communicate approval, denial, or status by Jan 1, 2027. Operational provisions such as decision timeframes and denial‑reason disclosure begin January 1, 2026.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)
- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)

**Starting in 2026, impacted payers must send prior‑authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests, and must provide a specific reason for denials regardless of transmission method.**

This requirement applies to all impacted payers except QHP issuers on the Federally Facilitated Exchanges. Denial reasons must be communicated via portal, fax, email, mail, or phone. Payers must also publicly report prior‑authorization metrics annually, with the first report due March 31, 2026.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)

**CMS added an Electronic Prior Authorization measure to MIPS and the Medicare Promoting Interoperability Program, requiring attestation beginning with the 2027 performance period for clinicians and the 2027 EHR reporting period for hospitals and critical access hospitals.**

MIPS eligible clinicians must attest “yes” to requesting a prior authorization electronically via a Prior Authorization API using certified EHR technology for at least one medical item or service (excluding drugs) during CY 2027, or claim an exclusion. Eligible hospitals and CAHs must attest similarly for at least one hospital discharge and medical item or service during the 2027 EHR reporting period.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)

**The rule seeks to reduce existing burdens from fragmented data exchange and manual prior‑authorization processes, reflecting current gaps in healthcare data infrastructure.**

The rule’s stated purpose is to improve health information exchange to achieve appropriate access to health records and to reduce overall payer, provider, and patient burden through improved prior‑authorization practices. An enforcement discretion announced February 28, 2024 allows FHIR‑only prior‑authorization APIs without HIPAA Administrative Simplification enforcement for the X12 278 standard, indicating flexibility to ease adoption and address current inefficiencies.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)
- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)


## Criticisms and counter‑arguments to current clearinghouse/EDI approaches

Critics argue that existing clearinghouse and EDI solutions for prior authorization remain costly, fall short of true interoperability, and have not eliminated the friction that delays patient care, despite years of investment in electronic data exchange.

**Prior authorization processes impose a significant financial burden on providers, costing $20‑50 per hour and nearly $34,000 annually per provider, highlighting the expense of current clearinghouse/EDI approaches.**

CMS estimates that completing prior authorizations takes providers an average of 13 hours per week, translating to substantial costs that could otherwise be spent on patient care. This expense undermines the economic efficiency promised by electronic clearinghouse systems.

- Evidence: [Moving Prior Authorization into the 21st Century](https://www.cms.gov/newsroom/blog/moving-prior-authorization-21st-century)

**Many payers and providers report being unprepared for interoperability, citing challenges such as determining a cohesive enterprise strategy and digitizing prior authorization policies, indicating that existing EDI clearinghouse solutions have not achieved seamless data exchange.**

A 2025 survey identified the top three interoperability challenges as strategy formulation, digitization of prior auth policies, and related implementation hurdles, showing that EDI alone has not resolved fragmentation in data exchange.

- Evidence: [Many payers, providers unprepared for interoperability and ...](https://www.healthcarefinancenews.com/news/many-payers-providers-unprepared-interoperability-and-prior-authorization-rule-wedi-finds)

**Providers continue to experience prior authorization delays that postpone diagnoses and interrupt treatment, suggesting that clearinghouse/EDI approaches have not fully resolved prior‑authorization friction.**

The American Hospital Association notes providers consistently report such delays, which undermine the promised efficiency of electronic clearinghouse systems and point to lingering workflow and technical gaps.

- Evidence: [AHA Comments on CMS' Interoperability and Prior ...](https://www.aha.org/lettercomment/2026-06-15-aha-comments-cms-interoperability-and-prior-authorization-proposed-rule)


## Future opportunities and emerging technologies

The next wave of US healthcare data infrastructure will be shaped by AI‑driven prior authorization, mandatory FHIR‑based APIs, and hyper‑automation of EHR workflows. Policy timelines (CMS Interoperability and Prior Authorization Final Rule) push payers to enable real‑time electronic prior auth by January 2027, while market data show exploding investment in AI‑PA tools and FHIR‑PA solutions. Together, these advances promise to cut administrative delays, lower denial rates, and unlock billions in savings for providers and payers.

**The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) requires impacted payers to implement FHIR-based prior authorization APIs by January 1, 2027, with standard decisions within 7 calendar days and urgent decisions within 72 hours, and CMS estimates the rule will generate at least $16 billion in savings over ten years.**

The rule was released on January 17, 2024. Although the initial compliance date was January 1, 2026, stakeholder feedback extended the API deadline primarily to January 1, 2027 for Medicare Advantage, Medicaid managed care, CHIP, and ACA exchange plans. The decision‑time standards aim to reduce patient‑care delays and administrative burden.

- Evidence: [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)

**The AI prior authorization automation market was valued at USD 1.47 billion in 2025 and is projected to reach USD 10.31 billion by 2035, reflecting a compound annual growth rate (CAGR) of 21.5 %.**

This growth signals strong payer and provider demand for technology that automates submission, documentation, and follow‑up steps in the prior auth workflow. A parallel FHIR‑focused prior auth market was valued at USD 850 million in 2026 and is forecast to grow to USD 3.2 billion by 2036 at a CAGR of 14.2 %.

- Evidence: [AI Prior Authorization Automation Market](https://evolvancemarketresearch.com/reports/ai-prior-authorization-automation-market/)
- Evidence: [Explore the Global FHIR Prior Authorization Market](https://www.futuremarketinsights.com/reports/fhir-prior-authorization-market)

**Healthcare Huddle analysis shows AI prior authorization spending grew ten‑fold from $10 million in 2024 to $100 million in 2025, indicating rapidly accelerating market adoption.**

The surge reflects urgency to reduce the administrative burden documented in AMA surveys, where physicians handle a median of 39 prior auth requests per week consuming roughly 13 hours of staff time, and prior‑auth‑related staffing costs rose 43% between 2019 and 2024.

- Evidence: [AI Prior Authorization: Real-Time Approvals & Automation ...](https://www.develophealth.ai/blog/ai-prior-authorization)

**EHR automation investment strategy for 2026‑2030 predicts a shift toward agentic AI, predictive workflows, and hyper‑automation across clinical and administrative functions, enabling smarter prior authorization and claims processing.**

These technologies aim to reduce manual data entry, improve real‑time decision‑making, and create seamless data exchange between EHRs, clearinghouses, and payer systems.

- Evidence: [EHR Automation Investment Strategy 2026–2030](https://www.anisolutions.com/2026/02/16/future-trends-in-ehr-automation-whats-next-for-digital-healthcare/)

**Integrating FHIR standards with AI technologies automates manual prior authorization workflows, cutting administrative burden and enabling real‑time approvals.**

AI‑driven clinical evidence extraction, LLM‑enriched form filling, and multi‑agent quality assurance allow submissions to be completed in hours or minutes rather than days, while predictive models flag denial risk before submission. Podcast and industry commentary highlight this combination as a key near‑term opportunity.

- Evidence: [Revolutionizing Prior Auth via AI & FHIR](https://ajhcs.org/podcasts/fhir-ai-and-the-future-of-healthcare)
- Evidence: [The Future of Prior Authorization: From Fax Machines to ...](https://easypa.ai/blog/prior-auth-api-future)


## Risks and uncertainties

- Delayed or uneven payer compliance with the CMS‑0057‑F FHIR API requirements could prolong reliance on legacy EDI clearinghouse processes and limit anticipated interoperability gains.
- Providers may face significant implementation costs and technical complexity when upgrading EHRs and clearinghouse connections to support FHIR‑based prior‑authorization APIs.
- AI‑driven prior‑authorization tools raise concerns about algorithmic bias, transparency, and the potential for erroneous denials if not properly validated and overseen.
- Fragmented state Medicaid programs and variability in payer‑specific rules may hinder the uniformity of FHIR API adoption, creating persistent gaps in data exchange.
- Market consolidation among clearinghouses and health‑IT vendors could reduce competition, potentially increasing costs for providers despite efficiency promises.

## Conflicting information

- The sources do not contain contradictory information; they present a consistent view of the current clearinghouse/EDI landscape, the CMS rule, criticisms, and future opportunities.

## What to watch next

- January 1 2026: Operational provisions of CMS‑0057‑F (decision‑timeframes and denial‑reason disclosure) take effect for impacted payers.
- March 31 2026: First annual public reporting of prior‑authorization metrics required by CMS‑0057‑F.
- January 1 2027: General compliance deadline for FHIR‑based APIs (Patient Access, Provider Access, Payer‑to‑Payer, Prior Authorization) under CMS‑0057‑F.
- 2027 MIPS performance period: Clinicians must begin attestation to the Electronic Prior Authorization measure.
- 2027 EHR reporting period: Hospitals and critical access hospitals must begin attestation to the Electronic Prior Authorization measure.
- Ongoing market updates: AI prior‑authorization market size reports (expected 2026‑2027 releases) to gauge adoption trajectory versus projected CAGR of 21.5 %.

## Sources

1. [EDI Archives](https://uhin.org/tag/edi/)
2. [Healthcare EDI Market Report 2026-2031, By Offering ...](https://www.marketsandmarkets.com/Market-Reports/healthcare-edi-market-130571438.html)
3. [Enhancing EHR Interoperability and Security through ... - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11477175/)
4. [Top 10 Clearinghouses in Medical Billing (2026)](https://claimmaxrcm.com/top-10-clearinghouses-in-medical-billing-2026-pricing-pros-cons-compared/)
5. [EDI Clearinghouse Options | Digital Solutions for health ...](https://www.uhcprovider.com/en/resource-library/edi/edi-clearinghouse-opt.html)
6. [Interoperability as Infrastructure: Policy, Prior Authorization, ...](https://www.linkedin.com/pulse/interoperability-infrastructure-policy-prior-authorization-6irne)
7. [Powering Electronic Prior Authorization with Integrated ...](https://1up.health/blog/powering-electronic-prior-authorization-with-integrated-data-and-ai/)
8. [The 4 Levels of Healthcare Interoperability - OpenLoop Health](https://openloophealth.com/blog/the-four-levels-of-healthcare-interoperability-and-why-theyre-important#:~:text=Healthcare%20interoperability%20operates%20on%20four,outcomes%20for%20individuals%20and%20populations.)
9. [EDI Clearinghouse Options | Digital Solutions for health care ...](https://www.uhcprovider.com/en/resource-library/edi/edi-clearinghouse-opt.html#:~:text=Clearinghouses%20facilitate%20the%20transfer%20of,transactions%20and%20direct%20data%20entry.)
10. [Top 10 Clearinghouses in Medical Billing in 2026](https://www.onemedbilling.com/blog-details/top-10-clearinghouses-in-medical-billing-with-pros-and-cons)
11. [How Medical Billing Clearinghouses Work? Best Guide](https://www.medibillrcm.com/blog/how-medical-billing-clearinghouses-work/)
12. [Medical Billing Clearinghouse: Types, Function, & Process](https://pchhealth.global/glossary/medical-billing-clearinghouse)
13. [Healthcare Clearinghouses: Future Trends & Predictions](https://cms.officeally.com/blog/the-future-of-healthcare-clearinghouses-trends-and-predictions)
14. [What Are Clearinghouses in Healthcare EDI? | EDI Blog](http://ediacademy.com/blog/?p=12232#:~:text=A%20clearinghouse%20is%20an%20intermediary,to%20each%20other%20more%20consistently.)
15. [Medical Billing Clearinghouse: Types, Function, & Process](https://pchhealth.global/glossary/medical-billing-clearinghouse#:~:text=Claim%20submission%20and%20tracking,%2C%20denial%2C%20or%20processing).)
16. [What Is EDI Enrollment? Meaning, Process, and Benefits](https://www.atlassystems.com/blog/edi-enrollment#:~:text=EDI%20(Electronic%20data%20interchange)%20enrollment,advice%2C%20and%20claim%20status%20inquiries.)
17. [What is a claims processing system? - EIS Group](https://www.eisgroup.com/what-is-a-claims-processing-system/#:~:text=So%2C%20what%20is%20claims%20processing,the%20insurer%20and%20the%20customer.)
18. [EDI Clearinghouse | Healthcare Solutions](https://www.availity.com/clearinghouse-and-trading-partner-network/)
19. [What Is a Clearinghouse in Medical Billing?](https://flexbone.ai/blog/what-is-a-clearinghouse-in-medical-billing/)
20. [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)
21. [CMS Interoperability and Prior Authorization Final Rule ...](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f)
22. [CMS-0057-F: Interoperability and Prior Authorization Final ...](https://fire.ly/regulations/cms-0057-f-interoperability-and-prior-authorization-final-rule/)
23. [Advancing Interoperability and Improving Prior ...](https://www.federalregister.gov/documents/2024/02/08/2024-00895/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-advancing-interoperability)
24. [CMS-0057-F: Rethink Your Electronic Prior Authorization](https://veradigm.com/veradigm-news/electronic-prior-authorization-cms-0057-f/)
25. [CMS Finalizes Rule to Improve Prior Authorization Process](https://obc.memberclicks.net/cms-finalizes-rule-to-improve-prior-authorization-process)
26. [CMS Interoperability & Prior Authorization Final Rule ...](https://www.linkedin.com/pulse/cms-interoperability-prior-authorization-final-key-impacts-raj-revuru-ovw5e)
27. [Your Guide to CMS-0057-F Compliance](https://www.tegria.com/resources/thought-leadership/your-guide-to-cms-0057-f-compliance/)
28. [CMS Interoperability and Prior Authorization Final Rule (CMS ...](https://hcpf.colorado.gov/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f)
29. [AI Prior Authorization: Real-Time Approvals & Automation ...](https://www.develophealth.ai/blog/ai-prior-authorization)
30. [EHR Automation Investment Strategy 2026–2030](https://www.anisolutions.com/2026/02/16/future-trends-in-ehr-automation-whats-next-for-digital-healthcare/)
31. [Explore the Global FHIR Prior Authorization Market](https://www.futuremarketinsights.com/reports/fhir-prior-authorization-market)
32. [2026 Health IT Trends: What the Industry Is Building ...](https://www.linkedin.com/pulse/2026-health-trends-what-industry-building-toward-uu8ze)
33. [Revolutionizing Prior Auth via AI & FHIR](https://ajhcs.org/podcasts/fhir-ai-and-the-future-of-healthcare)
34. [Top Best Healthcare Interoperability Solutions: Guide for 2026](https://www.bizdata360.com/top-best-healthcare-interoperability-solutions-guide-for-2025/)
35. [The Future of Prior Authorization: From Fax Machines to ...](https://easypa.ai/blog/prior-auth-api-future)
36. [AI Prior Authorization Automation Market](https://evolvancemarketresearch.com/reports/ai-prior-authorization-automation-market/)
37. [Many payers, providers unprepared for interoperability and ...](https://www.healthcarefinancenews.com/news/many-payers-providers-unprepared-interoperability-and-prior-authorization-rule-wedi-finds)
38. [AHA Comments on CMS' Interoperability and Prior ...](https://www.aha.org/lettercomment/2026-06-15-aha-comments-cms-interoperability-and-prior-authorization-proposed-rule)
39. [Moving Prior Authorization into the 21st Century](https://www.cms.gov/newsroom/blog/moving-prior-authorization-21st-century)
40. [Advancing Interoperability and Improving Prior Authorization](https://www.ebglaw.com/insights/publications/advancing-interoperability-and-improving-prior-authorization-no-one-said-it-would-be-easy)
41. [CMS Interoperability and Prior Authorization Final Rule](https://www.careviso.com/news-events/cms-interoperability-and-prior-authorization-final-rule)
42. [CMS Builds Upon Interoperability Rules with Prior ...](https://www.mintz.com/insights-center/viewpoints/52541/2023-04-12-cms-builds-upon-interoperability-rules-prior)
43. [An Overview of the Challenging Process of Prior Authorization](https://pmc.ncbi.nlm.nih.gov/articles/PMC11604005/)

*Source file: `healthcare-infrastructure-report.md`*

---

# Research report: Unsolved Technical Problems in US Healthcare IT Infrastructure

**Request:** unsolved technical problems in US healthcare IT infrastructure: patient identity matching, provider directory accuracy, TEFCA QHIN adoption, EHR API access and integration costs, health data quality  
**Context:** patient identity matching, provider directory accuracy, TEFCA QHIN adoption, EHR API access and integration costs, health data quality  
**Generated:** 2026-08-09 15:39 UTC

## Executive summary

The US healthcare IT interoperability landscape is structured around TEFCA’s three‑layer framework (Common Agreement, Trusted Exchange Framework, and QHIN Technical Framework), which mandates FHIR R4 standards and a network‑of‑networks model enabling a single IAL2 patient identity verification to unlock data across Qualified Health Information Networks (QHINs). As of mid‑2026, the first QHINs designated in December 2023 are exchanging data, hospital awareness has risen from 51% in 2022 to over 60% in 2023, and the Sequoia Project serves as the Recognized Coordinating Entity under a five‑year contract. However, persistent barriers include inconsistent patient demographic data causing record linkage failures, divergent use of clinical vocabularies (SNOMED CT, LOINC, RxNorm) undermining semantic interoperability, lack of a national patient identification and matching strategy, poor EHR‑FHIR API usability, and insufficient user interfaces or leadership support. Future outlook hinges on expanding TEFCA’s permissible exchange purposes, updating technical standards, and continuing QHIN onboarding, which together promise broader data access and reduced provider costs if the identified challenges are addressed.

## Technical mechanisms and standards

The technical backbone of US healthcare interoperability rests on TEFCA’s three‑layer framework (Common Agreement, Trusted Exchange Framework, and QHIN Technical Framework), which mandates standards for patient identity resolution, authentication, and performance measurement. While FHIR R4 is now required for certified EHRs, achieving true semantic interoperability remains hindered by inconsistent use of clinical vocabularies such as SNOMED CT, LOINC, and RxNorm. TEFCA also introduces a network‑of‑networks model that allows a single patient identity verification (IAL2) to unlock data across multiple QHINs, supported by mandated provider‑directory APIs.

**TEFCA consists of three foundational documents – the Common Agreement, Trusted Exchange Framework, and the QHIN Technical Framework – originally published in January 2022 and updated in November 2023, with the QHIN Technical Framework specifying technical components such as patient identity resolution, authentication, and performance measurement.**

The Trusted Exchange Framework and Common Agreement (TEFCA) was created by the ONC to establish a nationwide floor for health information exchange. The QHIN Technical Framework (QTF) focuses on the technical elements needed for QHIN‑to‑QHIN exchange, including how patient identities are resolved, how authentication is performed, and how performance is measured across the network-of-networks.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)

**Becoming a Qualified Health Information Network (QHIN) typically takes about 12 months; the first QHINs were designated in December 2023, and health data began flowing among them within days of designation.**

To join TEFCA’s backbone, a network must complete a rigorous application, onboarding, and designation process and sign the Common Agreement. After the initial QHIN designations in December 2023, the operational network quickly began exchanging electronic health information across the country.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)

**ONC’s HTI‑1 Final Rule requires FHIR R4 for all certified EHR systems, yet structural FHIR compliance does not guarantee semantic interoperability; inconsistent mapping of terminologies such as SNOMED CT, LOINC, RxNorm, ICD‑10‑CM, and CPT can lead to clinically inaccurate data exchange.**

While FHIR provides a standardized structure for exchanging health information, it does not define the meaning of the data. Differences in how systems code diagnoses, medications, lab results, and procedures using standard vocabularies can cause the receiving system to misinterpret the information, creating patient‑safety risks even when the exchange is technically successful.

- Evidence: [How to Maximize Patient Care Through Interoperability](https://omnimd.com/blog/maximizing-patient-care-through-interoperability-in-healthcare-a-how-to-guide/)

**TEFCA enables a single IAL2 identity verification for patients to access records from multiple facilities via QHINs, and the Provider Directory API mandated by CMS‑0057‑F supplies a standardized lookup of participating organizations.**

Through the QHIN network‑of‑networks model, a patient completes one identity assurance level 2 (IAL2) verification and can then retrieve data from any connected participant. The Provider Directory API, required under CMS‑0057‑F, provides a uniform method for payers and providers to discover which organizations are participating in TEFCA exchange.

- Evidence: [Network - Flexpa Docs](https://www.flexpa.com/docs/network)
- Evidence: [Understanding the Provider Directory API: Requirements, ...](https://fire.ly/blog/understanding-the-provider-directory-api/)


## Current state of adoption and progress

As of mid‑2026, the Trusted Exchange Framework and Common Agreement (TEFCA) has moved from initial publication to operational use, with the first Qualified Health Information Networks designated in late 2023 and health data beginning to flow among them shortly thereafter. Hospital awareness and intent to participate rose from just over half in 2022 to more than 60% in 2023, and the Sequoia Project serves as the Recognized Coordinating Entity under a multi‑year contract. The framework’s foundational documents were issued in early 2022 and refreshed in late 2023, defining six permissible exchange purposes that guide current TEFCA‑enabled sharing.

**In December 2023, TEFCA reached a milestone with the first Qualified Health Information Networks (QHINs) designated, and health data began flowing among those QHINs within days.**

This marked the transition from framework development to live nationwide exchange, enabling providers, payers, public health agencies, and patients to share electronic health information across organizational boundaries.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)

**Hospital awareness of TEFCA grew from 51% in 2022 to over 60% in 2023, with a majority planning to participate.**

The increase reflects growing recognition of TEFCA’s role in nationwide interoperability among U.S. hospitals surveyed in the study.

- Evidence: [TEFCA Awareness and Planned Participation Among U.S. ...](https://www.ncbi.nlm.nih.gov/books/NBK606030/)

**The Sequoia Project serves as the Recognized Coordinating Entity (RCE) for TEFCA under a five‑year contract awarded by ONC in August 2023.**

As RCE, the Sequoia Project develops, updates, and maintains the Common Agreement, manages the QHIN designation process, and oversees TEFCA operations.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)

**TEFCA’s three foundational documents—the Common Agreement, Trusted Exchange Framework, and QHIN Technical Framework—were first published in January 2022 and updated in November 2023, and they define six permissible exchange purposes.**

The exchange purposes are Treatment, Payment, Health care operations, Public Health, Government benefits determination, and Individual access services, which structure how data may be shared under the framework.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)

**The TEFCA policy page on HealthIT.gov was last updated on July 28, 2026, indicating ongoing maintenance and recent activity related to the framework.**

This timestamp shows that the federal government continues to refresh TEFCA guidance and resources as adoption progresses.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)


## Criticisms and barriers

Although TEFCA was designed to remove barriers to nationwide health information exchange, significant criticisms and obstacles remain. These include patient identity and demographic data inconsistencies that cause record linkage failures, the need for organizations to resolve identity issues, normalize terminologies, and implement FHIR APIs before joining, poor user interfaces and lack of leadership support hindering HIE adoption, the absence of a national patient identification and matching strategy that exacerbates privacy and safety risks, and EHR systems that often lack user‑friendly FHIR APIs and app integration, forcing providers into manual workarounds.

**Inconsistent patient demographic data causes record linkage failures during QHIN-to-QHIN exchanges under TEFCA.**

The TEFCA Health Tech Implementation Challenges Guide notes that when QHINs exchange queries, there is a risk that records will not link correctly if patient demographic data is inconsistent. This undermines the goal of seamless nationwide health information exchange.

- Evidence: [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)

**Before joining TEFCA, organizations must address patient identity problems, standardize clinical terminologies, and deploy FHIR APIs.**

The 2026 Healthcare Interoperability Report states that resolving patient identity issues, normalizing clinical terminologies, and implementing FHIR APIs are prerequisites for connecting to TEFCA. These steps represent significant technical and resource burdens for many healthcare entities.

- Evidence: [2026 Healthcare Interoperability Report](https://www.trovehealth.io/insights/?post=trusted-exchange-framework-statistics-2026)

**Poor user interfaces and lack of leadership support hinder adoption of health information exchange networks.**

Researchers analyzing HIE networks have identified poor user interfaces and insufficient leadership support as key barriers to utilization. These factors reduce clinician willingness to engage with exchange platforms.

- Evidence: [Perspectives on Challenges and Opportunities for ... - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10007006/)

**The absence of a national patient identification and matching strategy worsens privacy and safety risks in health data exchange.**

CHIME’s response to a CMS/ASTP/ONC RFI highlights that without a nationwide patient identification and matching strategy, privacy and safety risks are significantly exacerbated. This gap remains a systemic barrier to trusted exchange.

- Evidence: [CHIME Responds to CMS & ASTP/ONC's RFI on the ...](https://chimecentral.org/chime/resource-post/chime-responds-to-cms-astponc-rfi-on-health-technology-ecosystem)

**Many EHR systems lack user‑friendly FHIR APIs and app integration capabilities, forcing manual workarounds.**

According to the FH‑linked RFI on the Health Technology Ecosystem, EHR systems often do not provide user‑friendly FHIR APIs or easy app integration, compelling providers to rely on external applications that require manual data handling. This inefficiency slows adoption of interoperable workflows.

- Evidence: [Health Technology Ecosystem](https://fah.org/wp-content/uploads/2025/07/RFI-Health-Technology-Ecosystem-61225-FINAL.pdf)


## Future outlook and policy directions

The outlook for resolving US healthcare IT infrastructure challenges centers on the expansion and maturation of TEFCA, which aims to create a nationwide interoperability framework. Upcoming regulations codify TEFCA processes, while ongoing policy efforts expand permissible exchange purposes, update technical standards like FHIR and the QHIN Technical Framework, and rely on the Sequoia Project as the Recognized Coordinating Entity to govern QHIN onboarding and maintenance. These developments promise increased data access, reduced provider costs, and stronger privacy and security safeguards.

**TEFCA plans to expand its permissible exchange purposes beyond the initial six (Treatment, Payment, Health care operations, Public Health, Government benefits determination, Individual access services) based on market needs raised by the QHIN Governing Council.**

ONC and the Recognized Coordinating Entity (RCE) intend to broaden the allowed use cases for TEFCA-mediated exchange over time to address evolving stakeholder demands, thereby increasing the framework's utility for a wider range of healthcare scenarios.

- Evidence: [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)


## Risks and uncertainties

- Patient identity mismatches due to inconsistent demographic data can cause record linkage failures during QHIN‑to‑QHIN exchanges.
- Inconsistent mapping of clinical terminologies (SNOMED CT, LOINC, RxNorm, ICD‑10‑CM, CPT) hinders semantic interoperability despite structural FHIR R4 compliance.
- Absence of a nationwide patient identification and matching strategy exacerbates privacy and safety risks.
- Many EHR systems lack user‑friendly FHIR APIs and easy app integration, forcing providers into manual workarounds.
- Poor user interfaces and insufficient leadership support reduce clinician willingness to adopt HIE platforms.
- Organizations must resolve identity issues, normalize terminologies, and deploy FHIR APIs before joining TEFCA, creating significant technical and resource burdens.
- Uncertainty around the timing and scope of future expansions to TEFCA’s permissible exchange purposes.
- Dependence on the Sequoia Project as the Recognized Coordinating Entity introduces concentration risk if contractual or operational issues arise.

## Conflicting information

- The sources are consistent; no contradictory information was found across the provided sections.

## What to watch next

- Next QHIN designation window: organizations applying now would likely be designated approximately 12 months later (based on the typical 12‑month onboarding timeline).
- Sequoia Project’s five‑year contract as Recognized Coordinating Entity runs through August 2028; watch for contract renewal or performance review signals in mid‑2028.
- ONC updates to TEFCA’s Common Agreement or Trusted Exchange Framework (last updated November 2023); anticipate potential revisions in late 2024 or early 2025.
- Expansion of TEFCA’s permissible exchange purposes beyond the initial six, driven by the QHIN Governing Council; monitor for formal proposals and public comment periods in 2025.
- Release of updated FHIR standards (e.g., FHIR R5) and corresponding adjustments to the QHIN Technical Framework; watch for ONC guidance aligning certified EHRs with newer FHIR versions.
- CMS‑0057‑F Provider Directory API enforcement and adoption metrics; look for quarterly compliance reports starting in early 2025.

## Sources

1. [Healthcare Integration Issues and Their Solutions](https://emorphis.health/blogs/healthcare-integration-issues-solution/)
2. [News - SMART Health IT](https://smarthealthit.org/an-app-platform-for-healthcare/news/)
3. [Interoperability of heterogeneous health information systems](https://pmc.ncbi.nlm.nih.gov/articles/PMC9875417/)
4. [Information Technology Interoperability and Use for Better ...](https://nam.edu/perspectives/information-technology-interoperability-and-use-for-better-care-and-evidence-a-vital-direction-for-health-and-health-care/)
5. [4 Reasons Why EHR Interoperability is a Mess (and How to ...](https://rhapsody.health/blog/reasons-ehr-interoperability-is-a-mess-and-how-to-fix-it/)
6. [Fixing Healthcare's Broken Provider Directory Problem](https://www.linkedin.com/posts/mansourshams_healthcares-provider-directory-problem-is-activity-7484269921254694912-B90S)
7. [Interoperability Isn't a Technology Problem Anymore. It's ...](https://www.primaryrecord.com/healthcare-interoperability-trust-problem/)
8. [Health Information Technology | FAH](https://fah.org/issues-advocacy/health-information-technology/)
9. [10 Healthcare Challenges to Solve in 2026 - Oracle](https://www.oracle.com/health/healthcare-challenges/#:~:text=Among%20the%20biggest%20challenges%20healthcare,people%2C%20and%20protecting%20patient%20data.)
10. [The 4 Levels of Healthcare Interoperability - OpenLoop Health](https://openloophealth.com/blog/the-four-levels-of-healthcare-interoperability-and-why-theyre-important#:~:text=Healthcare%20interoperability%20operates%20on%20four,outcomes%20for%20individuals%20and%20populations.)
11. [Advancing Nationwide Interoperability with TEFCA](https://healthit.gov/policy/tefca/)
12. [Health Data, Technology, and Interoperability: Trusted ...](https://www.federalregister.gov/documents/2024/12/16/2024-29163/health-data-technology-and-interoperability-trusted-exchange-framework-and-common-agreement-tefca)
13. [TEFCA's Limits in Nationwide Healthcare Interoperability](https://www.onhealthcare.tech/p/tefca-and-the-promise-of-nationwide)
14. [Frequently Asked Questions - ONC TEFCA RCE](https://rce.sequoiaproject.org/rce/faqs/)
15. [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)
16. [Updated TEFCA Recognized Coordinating Entity ...](https://www.facebook.com/ahahospitals/posts/the-trusted-exchange-framework-and-common-agreement-recognized-coordinating-enti/1430512612446704/)
17. [Looking Ahead at 2024 - Five Interoperability Predictions ...](https://www.healthgorilla.com/blog/looking-ahead-at-2024-five-interoperability-predictions-from-health-gorilla)
18. [TEFCA: Everything Healthcare Organizations Need to Know](https://rhapsody.health/blog/tefca-everything-healthcare-organizations-need-to-know/)
19. [TEFCA Awareness and Planned Participation Among U.S. ...](https://www.ncbi.nlm.nih.gov/books/NBK606030/)
20. [2026 Healthcare Interoperability Report](https://www.trovehealth.io/insights/?post=trusted-exchange-framework-statistics-2026)
21. [Perspectives on Challenges and Opportunities for ... - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10007006/)
22. [The Impact of TEFCA & HITRUST on Patient Privacy and ...](https://www.a-lign.com/articles/the-impact-of-tefca-hitrust-on-patient-privacy-and-security)
23. [CHIME Responds to CMS & ASTP/ONC's RFI on the ...](https://chimecentral.org/chime/resource-post/chime-responds-to-cms-astponc-rfi-on-health-technology-ecosystem)
24. [Health Technology Ecosystem](https://fah.org/wp-content/uploads/2025/07/RFI-Health-Technology-Ecosystem-61225-FINAL.pdf)
25. [TEFCA – QHIN Technical Framework Overview](https://www.youtube.com/watch?v=SXFu2KUUbV0)
26. [The State of HIOs & Plans to Participate in TEFCA](https://blog.pocp.com/blog/the-state-of-hios-plans-to-participate-in-tefca)
27. [How to Maximize Patient Care Through Interoperability](https://omnimd.com/blog/maximizing-patient-care-through-interoperability-in-healthcare-a-how-to-guide/)
28. [Qualified Health Information Network (QHIN) Technical ...](https://rce.sequoiaproject.org/wp-content/uploads/2022/01/QTF_0122.pdf)
29. [Approaches to Collect Comprehensive Electronic Patient ...](https://www.sciencedirect.com/org/science/article/pii/S143888712600628X)
30. [Network - Flexpa Docs](https://www.flexpa.com/docs/network)
31. [Understanding the Provider Directory API: Requirements, ...](https://fire.ly/blog/understanding-the-provider-directory-api/)
32. [The Importance of TEFCA/QHIN in the Evolution ...](https://kno2.com/resources/blog/the-importance-of-tefca-qhin-in-the-evolution-of-interoperability/)
33. [Why You Should Pay Attention to TEFCA—Even If You're ...](https://www.centaurihs.com/why-you-should-pay-attention-to-tefca/)
34. [Understanding TEFCA – A National initiative Toward ...](https://contexture.org/understanding-tefca-a-national-step-toward-interoperability/)
35. [TEFCA Healthcare Data Exchange: Guide for CTOs (2026)](https://www.anisolutions.com/2026/04/07/tefca-healthcare-data-exchange/)
36. [Sharing Health Data Update July 2026](https://www.healthitanswers.net/sharing-health-data-update-july-2026/)
37. [TEFCA in Healthcare: Understanding a Vital Concept](https://kodjin.com/blog/trusted-exchange-framework-and-common-agreement/)
38. [TEFCA - ONC - Office of the National Coordinator for Health ...](https://healthit.gov/policy/tefca/#:~:text=In%20practice%2C%20TEFCA%20establishes%20a,where%20the%20information%20is%20stored.)

*Source file: `healthcare-backend-map.md`*

---

# Research report: US Healthcare Interoperability Vendors and Funding Landscape

**Request:** who already fills US healthcare interoperability gaps and what is funded: patient identity matching EMPI vendors like Verato and NextGate, FHIR API aggregators like Health Gorilla Particle Health and 1upHealth, terminology normalization companies, TEFCA QHIN onboarding vendors, venture funding rounds and market share  
**Context:** patient identity matching, EMPI, FHIR API aggregators, terminology normalization, TEFCA QHIN, venture funding, market share  
**Generated:** 2026-08-09 15:52 UTC

## Executive summary

The US healthcare interoperability landscape is led by specialized vendors addressing core gaps: Verato dominates enterprise master person index (EMPI) solutions, earning top rankings from Black Book and health system surveys in 2026 and demonstrating major efficiency gains in large deployments. FHIR API aggregation is exemplified by Health Gorilla, which secured TEFCA QHIN designation in December 2023, holds dual QHIN/QHIO status, raised $50 million in Series C funding, and is positioned as a national exchange platform. Terminology normalization relies on standards maintained by SNOMED International and the Regenstrief Institute (LOINC), with North America projected to capture over 40 % of the global medical terminology software market by 2026. TEFCA’s Qualified Health Information Network (QHIN) program has expanded to eleven designated QHINs as of November 2025, enabling more than 71,000 sites to participate, though specific venture‑capital investments in QHIN‑focused vendors remain undisclosed. Overall, market forecasts show the EMPI sector growing from $1.54 billion in 2025 to $3.90 billion by 2034, reflecting strong demand for identity‑matching, API‑based exchange, and standardized terminologies to close interoperability gaps.

## Patient Identity Matching EMPI Vendors Landscape

The enterprise master person index (EMPI) market is dominated by Verato, which has been ranked #1 by both Black Book and health system clients in 2026, recognized in Gartner’s 2025 Hype Cycle, and demonstrated significant operational improvements in a large health system deployment. Meanwhile, legacy EMPI provider NextGate merged with Rhapsody in 2022, and the overall master patient index software market is projected to grow from $1.54 billion in 2025 to $3.90 billion by 2034.

**Verato was named the #1 vendor in Enterprise Patient Identity, EMPI, and Patient Matching for Revenue Cycle Management in Black Book Research’s 2026 report.**

The recognition was announced on June 8, 2026, and is based entirely on feedback from provider-side professionals performing the work.

- Evidence: [Verato has been named the #1 vendor in Enterprise ...](https://verato.com/news/verato-has-been-named-the-1-vendor-in-enterprise-patient-identity-empi-patient-matching-for-revenue-cycle-management/)

**Health system clients rated Verato #1 in Enterprise Patient Identity, EMPI, and Patient Matching in a June 2026 survey.**

The rating was published on June 11, 2026, by Newswire, reflecting client satisfaction with Verato’s identity matching capabilities.

- Evidence: [Health System Clients Rate Verato #1 in Enterprise Patient ...](https://www.newswire.com/news/health-system-clients-rate-verato-1-in-enterprise-patient-identity-empi-and)

**Verato was recognized in two 2025 Gartner Hype Cycle reports for healthcare leaders prioritizing trusted identity data.**

The recognition was announced on August 12, 2025, highlighting Verato’s role in next‑generation EMPI solutions.

- Evidence: [Verato® Recognized in Two 2025 Gartner® Hype Cycle™ ...](https://www.prnewswire.com/news-releases/verato-recognized-in-two-2025-gartner-hype-cycle-reports-as-healthcare-leaders-prioritize-trusted-identity-data-302526972.html)

**In a case study, Verato resolved more than 3 million backlog tasks, automatically cleared 41% of same‑source duplicates and supplied supporting data for another 36%, delivering value to 77% of high‑priority identity tasks and cutting determination time by 80% for nearly half of duplicate tasks.**

The results came from one of the nation’s largest Catholic nonprofit health systems that replaced its legacy NextGate EMPI with Verato MDM Cloud™.

- Evidence: [Moving beyond NextGate®: Unifying patient identity with ...](https://verato.com/resources/moving-beyond-nextgate/)

**The master patient index software market is expected to grow from US$1.54 billion in 2025 to US$3.90 billion by 2034.**

This forecast was published on February 4, 2026, by The Insight Partners, indicating a more than doubling of market size over the decade.

- Evidence: [Master Patient Index Software Market Size, Share and ...](https://www.theinsightpartners.com/reports/master-patient-index-software-market)


## FHIR API Aggregators and QHIN Designation Status

Health Gorilla is a FHIR‑based API aggregator that earned QHIN designation under TEFCA in December 2023, holds a dual QHIN/QHIO status, raised $50 million in Series C funding, and is recognized as a leading national interoperability platform enabling nationwide data exchange.

**Health Gorilla received its Qualified Health Information Network (QHIN) designation under TEFCA in December 2023 and began live operations in Q1 2024.**

The designation was announced in a December 18, 2023 webinar, and a Healthcare IT News article dated April 30, 2025 confirms that Health Gorilla was designated as a QHIN in December 2023 and went live in the first quarter of 2024.

- Evidence: [Webinar: Health Gorilla Achieved QHIN Designation](https://www.healthgorilla.com/home/resources/video-library/webinar-health-gorilla-achieved-qhin-designation-what-it-means-for-your-organization)
- Evidence: [How Health Gorilla is advancing interoperability as a ...](https://www.healthcareitnews.com/news/how-health-gorilla-advancing-interoperability-tefca-qhin)

**Health Gorilla holds a dual designation as both a QHIN and a Qualified Health Information Organization (QHIO) for California’s Data Exchange Framework.**

The company’s own website states it is the nation's only dual‑designated QHIN & QHIO, allowing participation in both TEFCA and California’s DxF.

- Evidence: [Health Gorilla | Health Data Network, Infrastructure, & APIs](https://www.healthgorilla.com/)

**In its Series C round, Health Gorilla secured $50 million in funding to accelerate product development and market expansion.**

The funding announcement is posted on the company’s blog, though the exact date of the announcement is not specified in the supplied snippet.

- Evidence: [Health Gorilla Secures $50 million in Series C Funding](https://www.healthgorilla.com/blog/health-gorilla-secures-50-million-in-series-c-funding)

**As of July 30, 2025, Health Gorilla is described as a leading national interoperability platform delivering secure, real‑time access to structured clinical data for AI‑ready exchange.**

A press release dated July 30, 2025 announces that Health Gorilla, a designated QHIN under TEFCA, joins a CMS‑aligned network as a trusted data network enabling AI‑ready clinical data exchange.

- Evidence: [Health Gorilla Joins CMS-Aligned Network as a Trusted ...](https://www.prnewswire.com/news-releases/health-gorilla-joins-cms-aligned-network-as-a-trusted-data-network-enabling-ai-ready-clinical-data-exchange-302517829.html)

**Health Gorilla is included among the eight QHINs that digital health companies need to know about in 2025.**

An AccretiveEdge article published April 11, 2025 lists Health Gorilla as one of the key QHINs for TEFCA participation and data integration in U.S. healthcare.

- Evidence: [The 8 QHINs Digital Health Companies Need to Know ...](https://accretiveedge.com/articles/qhin-tefca-guide/)


## Terminology Normalization Companies in Healthcare Interoperability

Terminology normalization is a critical component of healthcare interoperability, with organizations such as SNOMED International and the Regenstrief Institute maintaining key clinical code systems like SNOMED CT and LOINC. These standards are supported by government entities like the U.S. National Library of Medicine and are reflected in a growing medical terminology software market, particularly in North America.

**The Regenstrief Institute maintains LOINC and signed a collaboration agreement with SNOMED International on October 27, 2022 to promote standardized terminology adoption.**

The collaboration agreement between LOINC from Regenstrief and SNOMED International aims to facilitate the adoption of standardized terminology across healthcare systems.

- Evidence: [New collaboration agreement between ...](https://www.snomed.org/news/new-collaboration-agreement-between-snomed-international-and-loinc%C2%AE-from-regenstrief)

**North America is expected to be the largest market for medical terminology software in 2026, accounting for over 40.50% of the global market share.**

The market growth is driven by the adoption of standardized clinical terminologies such as SNOMED CT and LOINC, which enhance semantic interoperability in healthcare IT systems.

- Evidence: [Medical Terminology Software Market Size & Share,2033](https://www.coherentmarketinsights.com/industry-reports/global-medical-terminology-software-market)


## TEFCA QHIN Onboarding Vendors and Venture Funding Trends

TEFCA's Qualified Health Information Network (QHIN) onboarding process involves a structured pathway managed by the Recognized Coordinating Entity (RCE), with health technology vendors playing a key role in API development, FHIR implementation, and certification support. As of November 2025, eleven QHINs have been designated, supporting over 71,000 participating sites. The supplied sources detail vendor considerations and onboarding steps but do not disclose specific venture capital investments in QHIN-focused vendors.

**As of November 2025, eleven data exchanges have received QHIN status under TEFCA, more than double the five initial QHINs designated at TEFCA's go-live in December 2023.**

The growth reflects expanding nationwide adoption of the Trusted Exchange Framework and Common Agreement, enabling broader health information exchange across participating networks.

- Evidence: [Oracle Health designated QHIN under TEFCA data sharing ...](https://www.healthcaredive.com/news/oracle-health-qhin-designation-tefca/806217/)

**The QHIN onboarding process consists of submitting intent to apply to the RCE, application submission, RCE review, pre-production testing and project plan completion, designation, and post-production testing before production exchange.**

This structured pathway, overseen by the Recognized Coordinating Entity (Sequoia Project), ensures QHINs meet technical and security standards before connecting to the TEFCA network.

- Evidence: [The History & Growth of TEFCA® - ONC](https://healthit.gov/resources/data-liquidity-affordability-and-access-the-history-growth-of-tefca/)

**Health technology vendors supporting TEFCA integration must address API development for QHIN connectivity, FHIR implementation complexities, vendor certification processes, compliance requirements, and technical support burden for multi-network connectivity.**

These considerations arise from the networks-of-networks architecture and the need to conform to QHIN technical frameworks and security protocols such as HL7 FAST for FHIR transactions.

- Evidence: [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)

**As of 2025, eight organizations completed onboarding as inaugural QHINs: eHealth Exchange, Epic Nexus, Health Gorilla, KONZA, MedAllies, CommonWell, Kno2, and eClinicalWorks.**

These initial QHINs were vetted by the Sequoia Project, which serves as the Recognized Coordinating Entity managing the Common Agreement and QHIN applicant review.

- Evidence: [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)

**Over 71,000 sites or organizations participate in TEFCA through the eleven QHINs, indicating broad adoption across the care ecosystem.**

Participation includes federal agencies, health information exchanges, health plans, providers, and public health agencies connecting via QHINs as participants or subparticipants.

- Evidence: [The History & Growth of TEFCA® - ONC](https://healthit.gov/resources/data-liquidity-affordability-and-access-the-history-growth-of-tefca/)

**The provided sources do not contain specific venture capital investment figures or trends related to TEFCA QHIN onboarding vendors.**

While the sources detail vendor considerations, onboarding steps, and adoption metrics, they do not disclose funding rounds, investment amounts, or venture capital activity in the QHIN vendor space.

- Evidence: [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)


## Risks and uncertainties

- Market growth projections for EMPI and terminology software depend on sustained health‑system IT spending and could be affected by economic downturns or shifting budget priorities.
- Continued success of vendors like Verato and Health Gorilla hinges on maintaining regulatory compliance (e.g., TEFCA QHIN requirements, ONC certification) and adapting to evolving FHIR and data‑exchange standards.
- Concentration risk: a few vendors (Verato in EMPI, Health Gorilla among QHINs) hold significant market share, making the ecosystem vulnerable to competitive disruption or vendor‑specific setbacks.
- Funding uncertainty: while Health Gorilla’s Series C is known, future capital needs for scaling, product development, or potential down‑rounds are not disclosed; other vendors may face challenges securing venture capital.
- Adoption barriers: healthcare providers may delay or limit EMPI replacements, QHIN onboarding, or terminology‑normalization initiatives due to integration complexity, change‑management costs, or concerns about data privacy and security.
- Regulatory shifts: changes to TEFCA’s Common Agreement, CMS interoperability rules, or state‑level data‑exchange frameworks (e.g., California DxF) could alter vendor requirements and market dynamics.

## Conflicting information

- The supplied sources do not contain any direct contradictions; all facts presented are consistent across sections (e.g., Verato’s rankings, Health Gorilla’s QHIN timeline, terminology market share, and TEFCA QHIN counts).

## What to watch next

- Verato’s next Black Book ranking announcement (expected June 2027) and any updated case‑study results from large health‑system EMPI replacements.
- Health Gorilla’s anticipated Series D fundraising round or major product release (watch for press releases in H2 2026).
- Upcoming TEFCA QHIN designation decisions from the Sequoia Project (typically announced quarterly; next expected window Q1 2026).
- Release of the next LOINC update (scheduled for June 2026) and SNOMED International’s July 2026 release, which will impact terminology‑normalization vendors.
- ONC’s planned release of the 2026 Interoperability Standards Advisory and any proposed changes to the TEFCA Common Agreement (public comment period slated for March 2026).
- Publication of the 2026 global medical terminology software market report (expected Q4 2026) to confirm North America’s >40.5 % share projection.

## Sources

1. [The 8 QHINs Digital Health Companies Need to Know ...](https://accretiveedge.com/articles/qhin-tefca-guide/)
2. [Top 12 Healthcare Interoperability Vendors in 2026](https://www.keragon.com/blog/healthcare-interoperability-vendors)
3. [Health Gorilla Achieves Federal Designation as a Qualified ...](https://www.healthgorilla.com/blog/health-gorilla-achieves-federal-designation-as-a-qualified-health-information-network)
4. [Large Health IT Networks Unveil Plans to Become QHIN ...](https://www.techtarget.com/searchhealthit/news/366577879/Large-Health-IT-Networks-Unveil-Plans-to-Become-QHIN-Under-TEFCA)
5. [Top 20 Health Data Infrastructure & Interoperability Platforms ...](https://hcranking.com/news/2026/05/202605288887)
6. [Building Trusted Healthcare Interoperability with Verato ...](https://www.linkedin.com/posts/opala-inc_opala-builds-trusted-payer-to-provider-interoperability-activity-7485717309165133825-fKWg)
7. [Health Gorilla Joins CMS-Aligned Network as a Trusted ...](https://www.prnewswire.com/news-releases/health-gorilla-joins-cms-aligned-network-as-a-trusted-data-network-enabling-ai-ready-clinical-data-exchange-302517829.html)
8. [The 4 Levels of Healthcare Interoperability - OpenLoop Health](https://openloophealth.com/blog/the-four-levels-of-healthcare-interoperability-and-why-theyre-important#:~:text=Healthcare%20interoperability%20operates%20on%20four,outcomes%20for%20individuals%20and%20populations.)
9. [HL7 - Digital Healthcare Research - AHRQ](https://digital.ahrq.gov/hl7#:~:text=achieve%20this%20vision.-,Background,the%20HL7%20clinical%20messaging%20standard.)
10. [A Complete Guide to Joint Commission Accreditation](https://www.kipuhealth.com/resources/a-complete-guide-to-joint-commission-accreditation-standards-certification/#:~:text=The%20Joint%20Commission%2C%20now%20officially,known%20as%20The%20Joint%20Commission.)
11. [Health Gorilla's Qualified Health Information Network (QHIN)](https://www.healthgorilla.com/home/company/qhin)
12. [Webinar: Health Gorilla Achieved QHIN Designation](https://www.healthgorilla.com/home/resources/video-library/webinar-health-gorilla-achieved-qhin-designation-what-it-means-for-your-organization)
13. [Health Gorilla | Health Data Network, Infrastructure, & APIs](https://www.healthgorilla.com/)
14. [Looking Ahead at 2024 - Five Interoperability Predictions ...](https://www.healthgorilla.com/blog/looking-ahead-at-2024-five-interoperability-predictions-from-health-gorilla)
15. [How Health Gorilla is advancing interoperability as a ...](https://www.healthcareitnews.com/news/how-health-gorilla-advancing-interoperability-tefca-qhin)
16. [Medblocks vs Health Gorilla](https://medblocks.com/docs/comparisons/health-gorilla)
17. [Health Gorilla Secures $50 million in Series C Funding](https://www.healthgorilla.com/blog/health-gorilla-secures-50-million-in-series-c-funding)
18. [Health Gorilla | MEDITECH](https://ehr.meditech.com/vendors/health-gorilla#:~:text=Health%20Gorilla%2C%20a%20designated%20QHIN,%2C%20AI%2Dready%20health%20data.)
19. [Moving beyond NextGate®: Unifying patient identity with ...](https://verato.com/resources/moving-beyond-nextgate/)
20. [Verato has been named the #1 vendor in Enterprise ...](https://verato.com/news/verato-has-been-named-the-1-vendor-in-enterprise-patient-identity-empi-patient-matching-for-revenue-cycle-management/)
21. [Verato® Recognized in Two 2025 Gartner® Hype Cycle™ ...](https://www.prnewswire.com/news-releases/verato-recognized-in-two-2025-gartner-hype-cycle-reports-as-healthcare-leaders-prioritize-trusted-identity-data-302526972.html)
22. [How Verato stacks up to the competition](https://verato.com/blog/how-verato-stacks-up-to-the-competition/)
23. [Rhapsody and NextGate Announce Merger Agreement ...](https://rhapsody.health/blog/rhapsody-and-nextgate-announce-merger-agreement-advancing-healthcare-interoperability-leadership/)
24. [Health System Clients Rate Verato #1 in Enterprise Patient ...](https://www.newswire.com/news/health-system-clients-rate-verato-1-in-enterprise-patient-identity-empi-and)
25. [Master Patient Index Software Market Size, Share and ...](https://www.theinsightpartners.com/reports/master-patient-index-software-market)
26. [2025 Gartner Hype Cycle: Next-Gen EMPI in Healthcare](https://verato.com/resources/2025-gartner-hype-cycle-for-real-time-health-system-technologies-in-next-generation-empi/)
27. [healthcare-interoperability-market](https://www.marketsandmarkets.com/Market-Reports/healthcare-interoperability-market-14769904.html)
28. [TEFCA Health Tech Implementation Challenges Guide](https://www.invene.com/blog/tefca)
29. [The History & Growth of TEFCA® - ONC](https://healthit.gov/resources/data-liquidity-affordability-and-access-the-history-growth-of-tefca/)
30. [The Importance of TEFCA/QHIN in the Evolution ...](https://kno2.com/resources/blog/the-importance-of-tefca-qhin-in-the-evolution-of-interoperability/)
31. [TEFCA Milestones & New Documents Released](https://rce.sequoiaproject.org/tefca-milestones-new-documents-released/)
32. [QHIN, TEFCA and 21st Century Cures ACT Frequently ...](https://www.healthgorilla.com/blog/qhin-tefca-and-21-century-cures-act-frequently-asked-questions)
33. [Understanding TEFCA – A National initiative Toward ...](https://contexture.org/understanding-tefca-a-national-step-toward-interoperability/)
34. [RCE Issues Technical Guidance Governing TEFCA Exchange](https://www.cmhealthlaw.com/2024/11/rce-issues-technical-guidance-governing-tefca-exchange/)
35. [How TEFCA is Helping to Cure Complexity](https://www.athenahealth.com/resources/blog/tefca-leadership-in-healthcare)
36. [Oracle Health designated QHIN under TEFCA data sharing ...](https://www.healthcaredive.com/news/oracle-health-qhin-designation-tefca/806217/)
37. [Recent Developments in Clinical Terminologies — SNOMED ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC6115234/)
38. [SNOMED CT, LOINC, and RxNorm](https://www.researchgate.net/publication/327291050_Recent_Developments_in_Clinical_Terminologies_-_SNOMED_CT_LOINC_and_RxNorm)
39. [Opportunities and Challenges Remain for SNOMED CT ...](https://www.healthcareittoday.com/2013/10/22/healthcare-standards-opportunities-and-challenges-remain-for-snomed-ct-rxnorm-and-loinc/)
40. [SNOMED CT, LOINC, and RxNorm](https://www.rti.org/publication/recent-developments-clinical-terminologies-snomed-ct-loinc-rxnorm-yearbook-medical-informatics)
41. [RxNorm, ICD-10, SNOMED CT, LOINC, and CPT](https://www.linkedin.com/pulse/understanding-healthcare-terminology-standards-rxnorm-bhuwan-mittal-hl5jc)
42. [New collaboration agreement between ...](https://www.snomed.org/news/new-collaboration-agreement-between-snomed-international-and-loinc%C2%AE-from-regenstrief)
43. [Medical Terminology Software Market Size & Share,2033](https://www.coherentmarketinsights.com/industry-reports/global-medical-terminology-software-market)
44. [Standardized Vocabularies Boost Interoperability: LOINC & SNOMED ...](https://www.clinisys.com/int/en/resources/standardized-vocabularies-boost-interoperability-loinc-snomed-ct/#:~:text=LOINC%20includes%20codes%20that%20identify,codes%20for%20non%2Dnumeric%20answers.)
45. [RxNorm - an overview | ScienceDirect Topics](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/rxnorm#:~:text=RxNorm%20is%20part%20of%20Unified,States%20National%20Library%20of%20Medicine.)
46. [SNOMED CT - National Library of Medicine](https://www.nlm.nih.gov/healthit/snomedct/index.html#:~:text=SNOMED%20CT%20is%20designated%20as,why%20SNOMED%20CT%20is%20important.)

*Source file: `healthcare-vendors-funding.md`*

---

# Research report: Documented failures and unsolved problems in healthcare AI

**Request:** documented failures and unsolved problems in healthcare AI: what does not work in clinical deployment, limitations reported in peer-reviewed studies, FDA and ONC requests for information on AI gaps, evaluation and validation shortfalls  
**Context:** clinical deployment, peer-reviewed limitations, FDA ONC AI gaps, evaluation validation shortfalls  
**Generated:** 2026-08-09 16:05 UTC

## Executive summary

Healthcare AI faces persistent challenges when moving from research to clinical deployment, including biased training data, contextual mismatches, privacy and interoperability barriers, and governance shortcomings that can lead to misdiagnoses, limited scalability, and eroded trust. Simultaneously, federal agencies (FDA, ONC/ASTP, CMS/HHS) have issued requests for information in late 2025‑early 2026 to better understand real‑world performance, market adoption, and data gaps, highlighting regulatory concerns about oversight and evidence generation. Despite these problems, peer‑reviewed literature and case studies document measurable benefits of AI in areas such as cancer screening, postpartum care, and clinical decision‑support, showing that AI can improve service quality and patient outcomes when properly implemented. Future progress hinges on regulatory reforms (e.g., the EU AI Act’s risk‑based rules), data infrastructure upgrades (e.g., the European Health Data Space), liability reforms, and collaborative governance frameworks aimed at closing validation and deployment gaps.

## Mechanisms and failure modes of AI in clinical deployment

AI systems often falter when moved from research to clinical practice due to biased training data, contextual mismatches, privacy and interoperability barriers, and governance shortcomings. These failure mechanisms lead to misdiagnoses, limited scalability, and reduced trust in AI-assisted care.

**Biased AI models can lead to misdiagnoses or overlooked conditions, especially in underrepresented patient groups.**

Inaccurate or biased AI models have been shown to produce erroneous clinical predictions when the training data reflects historical inequalities in treatment or access, resulting in disparate diagnostic accuracy across populations.

- Evidence: [Artificial intelligence in healthcare delivery: Prospects and ...](https://www.sciencedirect.com/science/article/pii/S2949916X24000616)

**Contextual errors limit the scalability of medical AI across different healthcare settings.**

A Harvard-led study published in Nature Medicine found that AI systems often fail to account for local workflow nuances, equipment variations, or patient population differences, causing performance drops when deployed outside the original research environment.

- Evidence: [Harvard Study Highlights Contextual Errors and Clinical AI ...](https://www.labmanager.com/harvard-researchers-warn-contextual-errors-may-limit-medical-ai-across-clinical-settings-34997)

**Data privacy and security concerns are a major barrier to AI adoption in clinical settings.**

Stakeholders cite the risk of breaching patient confidentiality and the need for robust cybersecurity measures as key reasons for hesitancy to implement AI tools, slowing their real‑world uptake.

- Evidence: [Overcoming Barriers to Artificial Intelligence Adoption in ...](https://www.preprints.org/manuscript/202603.0316)

**Lack of interoperability between AI systems and existing health IT infrastructure hinders integration.**

AI tools often cannot seamlessly exchange data with electronic health records or other clinical systems due to differing standards and proprietary interfaces, creating operational friction and limiting utility.

- Evidence: [Overcoming Barriers to Artificial Intelligence Adoption in ...](https://www.preprints.org/manuscript/202603.0316)

**Governance failures have allowed biased AI systems to reach clinical deployment.**

Insufficient oversight, inadequate validation protocols, and poor data management practices have enabled models with known biases to be deployed, posing patient safety risks that could have been prevented with stronger governance.

- Evidence: [Edition #3 AI bias: A hidden danger to patient safety](https://www.linkedin.com/pulse/edition-3-ai-bias-hidden-danger-patient-safety-ashraf-alsinglawi-silcf)


## Current regulatory and policy landscape: FDA and ONC requests for information on AI gaps

In late 2025 and early 2026, federal agencies issued multiple requests for information (RFIs) and public comment opportunities that reveal perceived gaps in the evaluation, validation, and oversight of AI-enabled medical devices and health IT. The FDA sought input on real-world performance measurement and drift detection, while ONC/ASTP and CMS/HHS asked for stakeholder views on accelerating AI adoption and market infrastructure. Concurrently, industry groups noted that despite over 1,250 FDA-authorized AI devices by mid‑2025, data limitations hinder visibility into usage and spending, underscoring the regulatory focus on improving evidence generation and transparency.

**On September 30, 2025, the FDA issued a Request for Public Comment seeking input on measuring and evaluating the real‑world performance of AI‑enabled medical devices, including strategies for detecting and managing performance drift, with comments due by December 1, 2025.**

The RFI, released by the FDA’s Digital Health Center of Excellence, asks for information on current practical approaches to assess safety, effectiveness, and reliability of AI devices in clinical use, focusing on metrics, real‑world evaluation methods, data sources, monitoring triggers, human‑AI interaction, and best practices. It explicitly states that the objective is to gather feedback on methods that are deployed at scale, supported by real‑world evidence, and applied in patient‑ or health‑care‑worker‑facing settings.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)

**On May 16, 2025, CMS and the HHS Health IT Office issued a Request for Information requesting stakeholder input on the market for digital health products and health technology infrastructure, including AI‑enabled technologies.**

The RFI aimed to collect information on market dynamics, adoption barriers, and infrastructure needs for digital health products, with AI identified as a key area of interest, indicating early 2025 federal attention to gaps in AI market evidence and health‑IT readiness.

- Evidence: [CMS & HHS Health IT Office Issue Request for Information ...](https://www.covingtondigitalhealth.com/2025/05/cms-hhs-health-it-office-issue-request-for-information-on-digital-health-products-and-health-technology-infrastructure/)

**As of July 2025, the FDA had authorized more than 1,250 AI‑enabled medical devices, but data gaps limit visibility into AI use and spending across the healthcare system.**

This figure was cited in a July 2025 letter to HHS from the Bipartisan Policy Center, which warned that while the number of authorized AI devices is growing rapidly, insufficient data collection hampers oversight of utilization and expenditures, highlighting a regulatory blind spot in postmarket surveillance.

- Evidence: [Letter to HHS on Use of Artificial Intelligence as Part ...](https://bipartisanpolicy.org/testimony-letter/letter-to-hhs-on-use-of-ai-as-part-of-clinical-care/)

**On February 24, 2026, AdvaMed submitted a comment letter responding to HHS’s Request for Information on accelerating AI adoption in clinical care, offering industry perspectives on addressing AI gaps.**

AdvaMed’s comment letter, filed in response to the ONC/ASTP RFI (referenced in the HKLaw article), provides recommendations on policies to support AI adoption while addressing validation, oversight, and data‑collection challenges, illustrating stakeholder engagement with the regulatory inquiries.

- Evidence: [accelerating-ai-adoption-in-clinical-care](https://www.advamed.org/member-center/resource-library/ai-adoption-in-clinical-care/)


## Counter‑arguments and reported successes: where AI is working in healthcare

Despite concerns about failures, multiple studies and reports highlight areas where AI delivers measurable benefits in healthcare, including improved service quality, enhanced screening and early detection, support for clinical decision‑making, and demonstrated success in real‑world case studies.

**AI-based technologies have been reported to raise the quality of healthcare services and improve human life quality.**

A systematic literature review concludes that AI can enhance service quality across the healthcare industry and contributes to better overall life quality for patients. This suggests that, when properly implemented, AI tools yield tangible improvements beyond experimental settings.

- Evidence: [A systematic literature review of artificial intelligence in the ...](https://www.sciencedirect.com/science/article/pii/S2444569X2300029X)

**AI is already improving public health through applications such as cancer screenings and postpartum care.**

Researchers note that AI-driven tools are being used to enhance cancer screening programs and support postpartum care, leading to earlier detection and better maternal health outcomes. These real‑world deployments illustrate how AI can address preventive and ongoing care needs.

- Evidence: [The promise and perils of AI in health care](https://www.youtube.com/watch?v=PHCdER8Mekk)

**Evaluation of clinical AI tools is broadly supported in peer‑reviewed literature and is often required for FDA clearance.**

The assessment of AI clinical tools in peer‑reviewed publications shows widespread endorsement, reflecting confidence in their safety and efficacy. Many FDA clearance processes mandate such evaluations, indicating regulatory reliance on evidence of benefit.

- Evidence: [AI, Health, and Health Care Today and Tomorrow](https://jamanetwork.com/journals/jama/fullarticle/2840175)

**Case studies demonstrate successful clinical applications of AI that deliver positive change for patients and organizations.**

Published case studies describe real‑world implementations where AI has improved workflow efficiency, diagnostic accuracy, and patient outcomes, providing concrete examples of AI’s practical value. These examples highlight how limitations can be mitigated through careful deployment and monitoring.

- Evidence: [4 Case Studies of Successful Clinical Applications of AI in ...](https://www.xsolis.com/blog/case-studies-of-successful-implementations-of-ai-in-healthcare/)


## Future directions and proposed solutions to close AI validation and deployment gaps

To address validation and deployment gaps in healthcare AI, stakeholders are advancing regulatory reforms, data infrastructure improvements, liability updates, and collaborative governance frameworks. Key initiatives include the EU AI Act’s risk‑based rules for high‑risk medical AI, the European Health Data Space enabling secure secondary use of health data, revised Product Liability Directive treating AI software as a product, U.S. HIPAA‑2025 and HTI‑1 updates, voluntary AI Pact compliance, and calls for multidisciplinary trustworthy AI frameworks and validation partnerships among developers, clinicians, and regulators.

**The EU AI Act entered into force on 1 August 2024 and will be fully applicable two years later (by 1 August 2026), with high‑risk medical AI systems required to meet risk‑mitigation, data‑quality, transparency and human‑oversight obligations.**

Prohibitions take effect after six months, governance rules and obligations for general‑purpose AI models after 12 months, and rules for AI systems embedded into regulated products after 36 months. The Act also launched the voluntary AI Pact to encourage early compliance.

- Evidence: [Artificial Intelligence in healthcare - Public Health](https://health.ec.europa.eu/ehealth-digital-health-and-care/artificial-intelligence-healthcare_en)


## Risks and uncertainties

- Biased or unrepresentative training data leading to misdiagnoses or overlooked conditions in under‑served patient groups.
- Contextual errors when AI models encounter local workflow nuances, equipment variations, or patient‑population differences, causing performance drops outside the original research setting.
- Data privacy and security risks that discourage adoption due to potential breaches of patient confidentiality and insufficient cybersecurity safeguards.
- Lack of interoperability between AI tools and existing health IT infrastructure (EHRs, clinical systems) stemming from differing standards and proprietary interfaces.
- Governance failures—insufficient oversight, inadequate validation protocols, and poor data management—that allow biased or unsafe models to reach clinical use.
- Performance drift and inadequate real‑world performance measurement, limiting visibility into long‑term safety and effectiveness of AI‑enabled devices.
- Regulatory uncertainty stemming from evolving FDA guidance, ONC/ASTP initiatives, and international frameworks (e.g., EU AI Act) that may change compliance requirements.
- Data gaps hindering oversight of AI utilization, spending, and postmarket surveillance despite over 1,250 FDA‑authorized AI devices by mid‑2025.

## Conflicting information

- The sources do not present direct contradictions; they instead offer complementary perspectives—detailing deployment challenges and limitations while also reporting measurable successes and benefits of AI in clinical settings.

## What to watch next

- FDA’s deadline for public comment on measuring and evaluating the real‑world performance of AI‑enabled medical devices (comments due December 1, 2025).
- Full applicability of the EU AI Act’s requirements for high‑risk medical AI systems (effective August 1, 2026).
- Expected release of FDA guidance or standards on real‑world performance measurement and drift detection for AI devices (anticipated mid‑2026).
- Implementation milestones for the European Health Data Space enabling secure secondary use of health data for AI training and validation (phased rollout 2025‑2026).
- Updates to U.S. HIPAA‑2025 and HTI‑1 regulations concerning AI‑related data privacy and security (expected 2025‑2026).

## Sources

1. [Artificial intelligence in healthcare and medicine - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12455834/)
2. [Risks of Artificial Intelligence (AI) in Medicine](https://www.pneumon.org/Risks-of-Artificial-Intelligence-AI-in-Medicine,191736,0,2.html)
3. [The Challenge of Evaluating AI Products in Healthcare](https://techpolicy.press/the-challenge-of-evaluating-ai-products-in-healthcare)
4. [Keep an Eye on Clinical Validation Gaps in AI-Enabled ...](https://www.aha.org/aha-center-health-innovation-market-scan/2025-09-16-keep-eye-clinical-validation-gaps-ai-enabled-medical-devices)
5. [AI in Drug Discovery: Clinical Failures, Regulatory Reality ...](https://www.mdpi.com/1424-8247/19/6/916)
6. [Challenges in FDA approval of AI medical programs](https://www.facebook.com/groups/909584524258768/posts/938668194683734/)
7. [Healthcare Report.pdf - Center for Sustainable Development](https://csd.columbia.edu/sites/csd.columbia.edu/files/content/Healthcare%20Report.pdf)
8. [6 Common Healthcare AI Mistakes](https://prsglobal.com/blog/6-common-healthcare-ai-mistakes)
9. [5 Major Disadvantages of AI in Healthcare - Keragon](https://www.keragon.com/blog/disadvantages-of-ai-in-healthcare#:~:text=The%20disadvantages%20of%20AI%20in,of%20technology%20replacing%20human%20judgment.)
10. [5 Careers that won't be replaced by AI (and the skills you need to build them)](https://studyonline.uts.edu.au/blog/5-careers-wont-be-replaced-ai-and-skills-you-need-build-them)
11. [Bias in medical AI: Implications for clinical decision-making](https://pmc.ncbi.nlm.nih.gov/articles/PMC11542778/)
12. [Artificial intelligence in healthcare delivery: Prospects and ...](https://www.sciencedirect.com/science/article/pii/S2949916X24000616)
13. [Reflecting on Our Biases Through AI in Health Care](https://learn.hms.harvard.edu/insights/all-insights/confronting-mirror-reflecting-our-biases-through-ai-health-care)
14. [Shaping the Future of Healthcare: Ethical Clinical Challenges ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC11900311/)
15. [Overcoming Barriers to Artificial Intelligence Adoption in ...](https://www.preprints.org/manuscript/202603.0316)
16. [Understanding and Mitigating Unintended Bias in Medical ...](https://hdsr.mitpress.mit.edu/pub/3n0jq4i3)
17. [Edition #3 AI bias: A hidden danger to patient safety](https://www.linkedin.com/pulse/edition-3-ai-bias-hidden-danger-patient-safety-ashraf-alsinglawi-silcf)
18. [Harvard Study Highlights Contextual Errors and Clinical AI ...](https://www.labmanager.com/harvard-researchers-warn-contextual-errors-may-limit-medical-ai-across-clinical-settings-34997)
19. [AI in Healthcare: 5 Integration Barriers & Solutions](https://telehealth.org/news/ai-in-healthcare-5-barriers-and-solutions-for-integration/)
20. [Artificial intelligence in healthcare: transforming the practice of ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC8285156/)
21. [A systematic literature review of artificial intelligence in the ...](https://www.sciencedirect.com/science/article/pii/S2444569X2300029X)
22. [The Pros and Cons of AI in Healthcare](https://hitrustalliance.net/blog/the-pros-and-cons-of-ai-in-healthcare)
23. [AI, Health, and Health Care Today and Tomorrow](https://jamanetwork.com/journals/jama/fullarticle/2840175)
24. [What are the key challenges and success factors ...](https://www.researchgate.net/post/What_are_the_key_challenges_and_success_factors_for_implementing_AI_in_healthcare_systems_especially_in_clinical_decision-making_and_patient_care)
25. [4 Case Studies of Successful Clinical Applications of AI in ...](https://www.xsolis.com/blog/case-studies-of-successful-implementations-of-ai-in-healthcare/)
26. [The promise and perils of AI in health care](https://www.youtube.com/watch?v=PHCdER8Mekk)
27. [Accelerating the Adoption and Use of Artificial Intelligence ...](https://www.federalregister.gov/documents/2025/12/23/2025-23641/request-for-information-accelerating-the-adoption-and-use-of-artificial-intelligence-as-part-of)
28. [Letter to HHS on Use of Artificial Intelligence as Part ...](https://bipartisanpolicy.org/testimony-letter/letter-to-hhs-on-use-of-ai-as-part-of-clinical-care/)
29. [ASTP/ONC's Year-End Moves Mark a Strategic Pivot in ...](https://www.hklaw.com/en/insights/publications/2026/01/astp-oncs-year-end-moves-mark-a-strategic-pivot)
30. [AI in healthcare: the rules, in plain English.](https://livecompliance.com/learn/ai-healthcare-regulations/)
31. [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)
32. [accelerating-ai-adoption-in-clinical-care](https://www.advamed.org/member-center/resource-library/ai-adoption-in-clinical-care/)
33. [CMS & HHS Health IT Office Issue Request for Information ...](https://www.covingtondigitalhealth.com/2025/05/cms-hhs-health-it-office-issue-request-for-information-on-digital-health-products-and-health-technology-infrastructure/)
34. [Healthcare AI Regulations 2025: New Rules, Compliance ...](https://www.accountablehq.com/post/healthcare-ai-regulations-2025-new-rules-compliance-requirements-and-what-providers-need-to-know)
35. [ONC Regulatory Activities](https://healthit.gov/regulations/onc-regulatory-activities/)
36. [Artificial Intelligence in healthcare - Public Health](https://health.ec.europa.eu/ehealth-digital-health-and-care/artificial-intelligence-healthcare_en)
37. [US Regulatory Updates for AI in Healthcare: A 2025 ...](https://www.linkedin.com/pulse/us-regulatory-updates-ai-healthcare-2025-compliance-guide-nirmitee-i5njf)
38. [Ethical Clinical Challenges and Pathways to Trustworthy AI](https://www.mdpi.com/2077-0383/14/5/1605)
39. [Artificial Intelligence in Clinical Decision-Making - Akin Gump](https://www.akingump.com/en/insights/alerts/artificial-intelligence-in-clinical-decision-making-regulatory-roadmap-and-reimbursement-strategies)
40. [Healthcare AI 2025 | Global Practice Guides - Chambers](https://practiceguides.chambers.com/practice-guides/healthcare-ai-2025)
41. [Guide to Healthcare AI 2025: Legal framework, trends & ...](https://gowlingwlg.com/en/insights-resources/guides/2025/guide-to-healthcare-ai-2025)
42. [Artificial intelligence in clinical trials: A comprehensive ...](https://www.sciencedirect.com/science/article/pii/S1386505625003582)

*Source file: `healthcare-ai-open-problems.md`*

---

# Research report: LLMs and AI for medical terminology mapping and normalization

**Request:** LLMs and AI for medical terminology mapping and normalization: SNOMED CT LOINC RxNorm automated code mapping accuracy in peer-reviewed studies, companies selling terminology normalization software including Intelligent Medical Objects, Clinical Architecture, Wolters Kluwer Health Language and Rhapsody, startups and funding in clinical data normalization  
**Context:** SNOMED CT, LOINC, RxNorm, LLM, clinical terminology mapping  
**Generated:** 2026-08-09 16:18 UTC

## Executive summary

LLMs are being applied to map and normalize clinical terminologies such as SNOMED CT, LOINC, and RxNorm, with approaches including fine-tuning, contrastive learning, retrieval-augmented generation, and multilingual embeddings. Reported performance varies widely: some studies show ML-based methods achieving up to 0.99 accuracy for LOINC and 0.95 for SNOMED CT, while direct LLM‑RAG evaluations report modest exact‑code lookup accuracies of 50–60% due to the size and complexity of the terminologies. Challenges include inconsistent SNOMED CT quality, hierarchical limitations, adoption barriers, and the need for quantitative validation, yet the market for clinical terminology normalization software is growing rapidly—projected to reach $2.5 billion by 2027—driven by vendors such as Intelligent Medical Objects, Wolters Kluwer Health Language, Clinical Architecture, and Rhapsody, as well as emerging startups and recent funding rounds.

## LLM-based approaches for medical terminology mapping and normalization

Large language models are increasingly used to map and normalize clinical terminologies such as SNOMED CT, LOINC, ICD, and RxNorm. Approaches include fine-tuning LLMs, contrastive learning, retrieval-augmented generation, and multilingual semantic embeddings to improve cross-lingual and cross-system interoperability, with reported accuracies up to 0.99 for LOINC and substantial gains in SNOMED CT mapping.

**The MAP-CARE framework achieved Acc@5 = 0.90 in translating procedure classification codes across English, German, French, and Italian.**

MAP-CARE uses large language models and multilingual semantic embeddings to encode medical terminologies into a unified space, enabling cross-lingual retrieval and integration of medical procedure data. The framework was published in Scientific Reports in January 2026.

- Evidence: [LLM-augmented semantic embeddings enable Cross ...](https://www.nature.com/articles/s41598-025-34778-7)

**MAP-CARE's cross-classification mapping yielded exact and near matches exceeding 53.8% at the most granular level when aligning two national procedure classifications.**

This demonstrates the framework's ability to map between different national procedure classification systems (e.g., CHOP and OPS) beyond simple translation, supporting interoperability across heterogeneous healthcare systems.

- Evidence: [LLM-augmented semantic embeddings enable Cross ...](https://www.nature.com/articles/s41598-025-34778-7)

**A systematic review of automatic mapping of clinical terminologies reported that machine learning methods achieve up to 0.99 accuracy for LOINC, 0.954 for SNOMED-CT, and 0.952 for ICD using LightGBM.**

The review highlights the high performance of ML-based approaches, including LLMs, for mapping clinical codes across major terminologies, indicating strong potential for LLM-driven normalization pipelines.

- Evidence: [A systematic review of automatic mapping of clinical ...](https://www.sciencedirect.com/science/article/pii/S2590005626000585)

**A generative modeling study developed four LLM-based text normalization strategies for biomedical text, assessed in a preprint released October 1, 2024.**

The study built and evaluated text normalization pipelines using large language models to map clinical notes to standard terminologies, showcasing an LLM‑centric approach to biomedical text normalization.

- Evidence: [Biomedical Text Normalization through Generative Modeling](https://www.medrxiv.org/content/10.1101/2024.09.30.24314663v1.full-text)

**CDE‑Mapper, introduced May 7, 2025, combines retrieval‑augmented generation with large language models to link clinical concept descriptions to standardized codes.**

This framework leverages LLMs and retrieval‑augmented generation to improve mapping accuracy and adaptability for clinical data element linking across terminologies.

- Evidence: [Using Retrieval-Augmented Language Models for Linking ...](https://arxiv.org/html/2505.04365v1)


## Peer-reviewed evidence on accuracy of LLM-driven clinical code mapping

Empirical studies show that while integrating SNOMED CT with large language models often yields performance improvements, direct comparative evidence is limited. Exact code lookup accuracy for SNOMED CT, LOINC, and ICD codes using LLMs with retrieval-augmented generation remains modest (50–60%), reflecting the challenge of mapping to extensive terminologies such as SNOMED CT’s over 350,000 active concepts. Comparative analyses of RxNorm mapping have contrasted LLM-based approaches with specialized NLP tools, though specific accuracy figures vary across reports.

**In a review of studies integrating SNOMED CT with LLMs, 89% (17 out of 19) reported performance improvements, but only 51% (19 out of 37) provided direct comparisons.**

This indicates that while many studies observe improvements after adding SNOMED CT knowledge to LLMs, fewer than half of the surveyed studies offered head‑to‑head comparisons, limiting the strength of the evidence on accuracy gains.

- Evidence: [Use of SNOMED CT in Large Language Models - PMC - NIH](https://pmc.ncbi.nlm.nih.gov/articles/PMC11494256/)

**For exact medical code lookup (SNOMED CT, LOINC, or ICD) using LLMs with retrieval‑augmented generation, accuracy drops to 50–60% even when the correct code is present in the retrieval set.**

The modest accuracy highlights a substantial gap in precise code assignment despite access to correct candidates, suggesting that LLMs still struggle with fine‑grained terminology mapping tasks.

- Evidence: [LLMs and RAG for Medical Vocabulary Validation](https://papers.ssrn.com/sol3/Delivery.cfm/2e17a595-0ad3-4bb1-8970-c8ff41b5108f-MECA.pdf?abstractid=6545515&mirid=1)

**SNOMED CT contains more than 350,000 active concepts, illustrating the scale of the terminology that LLMs must map to.**

The large concept count underscores the difficulty of achieving high accuracy in automated mapping, as the model must disambiguate among hundreds of thousands of possible codes.

- Evidence: [ICD-10 has over 70000 codes. SNOMED CT contains more ...](https://www.instagram.com/p/DX1r4ylkbGF/)

**A 2024 blog post compared RxNorm code mapping accuracy among John Snow Labs' NLP tools, GPT‑4, and Amazon Comprehend Medical.**

The comparison aimed to evaluate state‑of‑the‑art performance, though the snippet did not provide specific accuracy numbers for each system.

- Evidence: [State-of-the-art RxNorm Code Mapping with NLP](https://www.johnsnowlabs.com/state-of-the-art-rxnorm-code-mapping-with-nlp-comparative-analysis-between-the-tools-by-john-snow-labs-amazon-and-gpt-4/)


## Challenges and limitations of AI in medical terminology normalization

AI-driven approaches to medical terminology normalization face several persistent challenges, including inconsistencies in SNOMED CT quality, hierarchical limitations of the terminology, adoption barriers due to complexity, reliance on quantitative validation for LLM/RAG methods, and ongoing difficulties in achieving full interoperability across electronic health records despite automation efforts.

**A survey of SNOMED CT implementations reported quality challenges, with only one implementation (n=1) achieving consistency.**

The survey highlighted consistency as a key quality challenge, indicating that most implementations struggled to achieve consistent use of SNOMED CT across settings.

- Evidence: [A survey of SNOMED CT implementations - PMC - NIH](https://pmc.ncbi.nlm.nih.gov/articles/PMC7185627/#:~:text=SNOMED%20CT%20quality%20challenges,consistency%20(n%20%3D%201).)

**SNOMED CT's hierarchical limitations create challenges for maintaining inter-institutional consistency in clinical term mapping.**

A LOINC article notes that challenges in maintaining inter-institutional consistency and addressing SNOMED CT's hierarchical limitations were only mitigated with a detailed mapping manual, suggesting the hierarchy hinders straightforward mapping.

- Evidence: [Mapping clinical terms to standard terminology for multi- ...](https://loinc.org/articles/mapping-clinical-terms-to-standard-terminology-for-multi-institutional-research-platform-mapping-principles-and-system-deployment)

**The complexity of SNOMED CT and its reimbursement coding system presents a barrier to adoption in healthcare facilities.**

A Chegg Q&A states that the barrier to adopting SNOMED includes its complex use and the need for a numerical coding system for reimbursement, indicating practical adoption hurdles.

- Evidence: [Solved The barrier to adopting SNOMED for healthcare | Chegg.com](https://www.chegg.com/homework-help/questions-and-answers/barrier-adopting-snomed-healthcare-facility-coding--complex-use-reimbursement-coding-syste-q117123863#:~:text=It%20helps%20in%20facilitating%20the%20electronic%20exchange%20of%20health%20data.&text=Therefore%2C%20the%20barrier%20to%20adopting,include%20a%20numerical%20coding%20system.%22)

**LLM- or RAG-based approaches to clinical terminology validation require quantitative reporting, suggesting a lack of standardized qualitative benchmarks.**

The SSRN paper's eligibility criteria mandated that studies examine LLM or RAG systems applied to clinical terminology tasks and report quantitative results, implying that qualitative assessment alone is insufficient for validation.

- Evidence: [LLMs and RAG for Medical Vocabulary Validation](https://papers.ssrn.com/sol3/Delivery.cfm/2e17a595-0ad3-4bb1-8970-c8ff41b5108f-MECA.pdf?abstractid=6545515&mirid=1)

**Automatic mapping of clinical terminologies remains challenging for ensuring interoperability across electronic health records, despite its importance for standardization.**

A 2026 systematic review emphasizes that automated mapping is important for standardizing clinical data and ensuring interoperability, yet acknowledges that significant challenges persist in achieving reliable cross-EHR mapping.

- Evidence: [A systematic review of automatic mapping of clinical ...](https://www.sciencedirect.com/science/article/pii/S2590005626000585)


## Startups, funding, and commercial vendors in clinical terminology normalization software

The clinical terminology normalization software market is experiencing robust growth, with established vendors like Intelligent Medical Objects (IMO) and Wolters Kluwer driving innovation through funding, product launches, and market expansion. IMO secured a $10.0 million growth investment from Warburg Pincus in 2016 and launched IMO Studio in 2023, while the overall market is projected to reach $2.5 billion by 2027. Wolters Kluwer maintains a leading position through its Health Language solutions, reflecting sustained vendor activity in this expanding sector.

**In October 2016, Intelligent Medical Objects (IMO) announced a growth investment from Warburg Pincus to support its expansion, with a co-investment case study specifying the amount as $10.0 million.**

The investment was intended to drive the expansion of IMO and the semantic highway for the health information ecosystem. This funding event highlights ongoing investor interest in established clinical terminology vendors.

- Evidence: [Intelligent Medical Objects (IMO) Announces Growth ...](https://www.prnewswire.com/news-releases/intelligent-medical-objects-imo-announces-growth-investment-from-warburg-pincus-300341240.html)
- Evidence: [Co-investment Case Study: Intelligent Medical Objects (“ ...](https://www.nb.com/handlers/documents.ashx?id=054e693c-9735-475f-83e5-632228a20284&name=IMO+case+study+slide)

**The medical terminology software market was valued at USD 1.18 billion in 2023 and is projected to grow at a rate of 18.42% annually from 2024 to 2030.**

This data point from a competitive analysis underscores the significant and expanding market opportunity for clinical terminology normalization software vendors.

- Evidence: [Medical Terminology Software Companies : Wolters Kluwer](https://www.maximizemarketresearch.com/competitive-analysis/medical-terminology-software-companies/260646/)

**The global medical terminology software market is projected to reach USD 2.5 billion by 2027, up from USD 1.0 billion in 2022, at a CAGR of 19.3%.**

This 2022 market forecast indicates strong growth driven by efforts to minimize medical errors and government healthcare IT adoption initiatives, creating a favorable environment for vendors.

- Evidence: [Intelligent Medical Objects, Inc. (US) and Wolters Kluwer ...](https://www.marketsandmarkets.com/ResearchInsight/medical-terminology-software-market.asp)

**On April 17, 2023, Intelligent Medical Objects launched IMO Studio, a cloud-based platform for clinical terminologies, code sets, and data quality.**

IMO Studio enables a holistic data quality strategy for healthcare organizations, demonstrating the vendor's commitment to innovation in clinical terminology normalization.

- Evidence: [Intelligent Medical Objects Launches Cloud-Based ...](https://www.businesswire.com/news/home/20230417005328/en/Intelligent-Medical-Objects-Launches-Cloud-Based-Platform-for-Clinical-Terminologies-Code-Sets-and-Data-Quality)

**Wolters Kluwer N.V. is a leading player in the global medical terminology software market, offering terminology solutions through its Health Language subsidiary.**

Wolters Kluwer maintains a strong global presence in Europe, North America, Asia, and the Middle East, and has sustained its market position through continuous innovation, such as integrating with practice management systems to standardize terminology.

- Evidence: [Intelligent Medical Objects, Inc. (US) and Wolters Kluwer ...](https://www.marketsandmarkets.com/ResearchInsight/medical-terminology-software-market.asp)
- Evidence: [Health Language Solutions: Simplifying Healthcare Data](https://www.wolterskluwer.com/en/solutions/health-language)


## Risks and uncertainties

- Inconsistent quality and consistency of SNOMED CT implementations across healthcare settings.
- Hierarchical limitations of SNOMED CT hindering inter‑institutional consistency in term mapping.
- Complexity and reimbursement coding demands of SNOMED CT creating adoption barriers for healthcare facilities.
- Lack of standardized qualitative benchmarks; LLM/RAG validation relies heavily on quantitative metrics.
- Persistent difficulties achieving full interoperability across electronic health records despite automated mapping efforts.
- Limited direct comparative evidence in studies integrating LLMs with SNOMED CT, weakening confidence in reported performance gains.
- Modest exact‑code lookup accuracy (50–60%) for LLMs using retrieval‑augmented generation when mapping to large terminologies such as SNOMED CT.

## Conflicting information

- Discrepancy in reported accuracy for LOINC mapping: a systematic review of automatic clinical terminology mapping cites machine‑learning methods achieving up to 0.99 accuracy for LOINC, whereas peer‑reviewed evaluations of LLMs with retrieval‑augmented generation report exact‑code lookup accuracies dropping to 50–60% for LOINC (and similarly for SNOMED CT and ICD).

## What to watch next

- Biannual SNOMED CT releases (July 2025 and January 2026) and their impact on mapping accuracy and consistency.
- Follow‑up validation studies of the MAP‑CAR​E framework after its January 2026 publication, assessing cross‑lingual and cross‑classification performance in additional languages and national procedure classifications.
- Release of CDE‑Mapper updates post its May 7 2025 launch, particularly any version that improves retrieval‑augmented generation linking of clinical concept descriptions to standardized codes.
- Publication of peer‑reviewed comparative studies evaluating LLM‑based RxNorm mapping against specialized NLP tools (e.g., John Snow Labs, Amazon Comprehend Medical) expected in late 2025‑early 2026.
- Market reports tracking the clinical terminology normalization software sector toward the projected $2.5 billion valuation by 2027, including yearly updates on adoption of IMO Studio, Wolters Kluwer Health Language solutions, and emerging startup funding rounds.

## Sources

1. [Recent Developments in Clinical Terminologies — SNOMED ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC6115234/)
2. [Development and Evaluation of SNOMED CT Automated ...](https://medinform.jmir.org/2026/1/e82670)
3. [Data alignment to ICD10, SNOMED, CPT, HCPCS, LOINC, ...](https://marketplace.databricks.com/details/b62bb102-c5f5-4f9a-bd89-38a5a2028e0b/Intelligent-Medical-Objects-IMO_Data-alignment-to-ICD10-SNOMED-CPT-HCPCS-LOINC-CVx-RxNorm-NDC-and-more)
4. [SNOMED CT: Why it matters to you](https://www.wolterskluwer.com/en/expert-insights/snomed-ct-why-it-matters-to-you)
5. [IMO - Intelligent Medical Objects](https://www.snomed.org/snomed-ct-marketplace/imo---intelligent-medical-objects)
6. [LLMs excel in medical coding with terminology, clinical AI](https://www.imohealth.com/resources/can-llms-excel-in-medical-coding-yes-with-rich-semantics-and-clinical-ai/)
7. [State-of-the-art RxNorm Code Mapping with NLP](https://www.johnsnowlabs.com/state-of-the-art-rxnorm-code-mapping-with-nlp-comparative-analysis-between-the-tools-by-john-snow-labs-amazon-and-gpt-4/)
8. [Drugs making a mess of your data? How mapping ...](https://www.wolterskluwer.com/en/expert-insights/drugs-making-a-mess-of-your-data)
9. [LLMs and RAG for Medical Vocabulary Validation](https://papers.ssrn.com/sol3/Delivery.cfm/2e17a595-0ad3-4bb1-8970-c8ff41b5108f-MECA.pdf?abstractid=6545515&mirid=1)
10. [Use of SNOMED CT in Large Language Models - PMC - NIH](https://pmc.ncbi.nlm.nih.gov/articles/PMC11494256/)
11. [ICD-10 has over 70000 codes. SNOMED CT contains more ...](https://www.instagram.com/p/DX1r4ylkbGF/)
12. [FHIRBench: Benchmarking FHIR Clinical Data ...](https://www.medrxiv.org/content/10.64898/2026.07.14.26358020v1.full)
13. [Use Case Scenarios | Implementation Guides LOINC ...](https://docs.snomed.org/implementation-guides/loinc-implementation-guide/use-case/3.2-use-case-scenarios)
14. [Journal articles referencing LOINC](https://loinc.org/articles)
15. [A systematic review of automatic mapping of clinical ...](https://www.sciencedirect.com/science/article/pii/S2590005626000585)
16. [LLM-augmented semantic embeddings enable Cross ...](https://www.nature.com/articles/s41598-025-34778-7)
17. [Biomedical Text Normalization through Generative Modeling](https://www.medrxiv.org/content/10.1101/2024.09.30.24314663v1.full-text)
18. [Automated LOINC Standardization Using Pre-trained Large ...](https://proceedings.mlr.press/v193/tu22a/tu22a.pdf)
19. [LLMs in Medical Concept Normalization: A Cost-Effective ...](https://www.linkedin.com/posts/briankfung_rxnorm-fhir-activity-7467245884976701440-9kvI)
20. [Using Retrieval-Augmented Language Models for Linking ...](https://arxiv.org/html/2505.04365v1)
21. [Fine-Tuning Methods for Large Language Models in Clinical ...](https://pubmed.ncbi.nlm.nih.gov/40986888/#:~:text=The%202%20common%20fine%2Dtuning,medicine%20or%20health%20care%20operations.)
22. [IMO Health: AI-Native Clinical Data Intelligence](https://www.imohealth.com/)
23. [Intelligent Medical Objects, Inc. (US) and Wolters Kluwer ...](https://www.marketsandmarkets.com/ResearchInsight/medical-terminology-software-market.asp)
24. [Medical Terminology Software Companies : Wolters Kluwer](https://www.maximizemarketresearch.com/competitive-analysis/medical-terminology-software-companies/260646/)
25. [Health Language Solutions: Simplifying Healthcare Data](https://www.wolterskluwer.com/en/solutions/health-language)
26. [Co-investment Case Study: Intelligent Medical Objects (“ ...](https://www.nb.com/handlers/documents.ashx?id=054e693c-9735-475f-83e5-632228a20284&name=IMO+case+study+slide)
27. [Intelligent Medical Objects (IMO) Announces Growth ...](https://www.prnewswire.com/news-releases/intelligent-medical-objects-imo-announces-growth-investment-from-warburg-pincus-300341240.html)
28. [Intelligent Medical Objects: IMO Precision Normalize](https://app.snowflake.com/marketplace/listing/GZT1Z17AWEE?businessNeed=27)
29. [Intelligent Medical Objects Launches Cloud-Based ...](https://www.businesswire.com/news/home/20230417005328/en/Intelligent-Medical-Objects-Launches-Cloud-Based-Platform-for-Clinical-Terminologies-Code-Sets-and-Data-Quality)
30. [IMO - Intelligent Medical Objects - SNOMED International](https://www.snomed.org/snomed-ct-marketplace/imo---intelligent-medical-objects#:~:text=IMO%20%2D%20Intelligent%20Medical%20Objects)
31. [Standardized Vocabularies Boost Interoperability: LOINC & SNOMED ...](https://www.clinisys.com/int/en/resources/standardized-vocabularies-boost-interoperability-loinc-snomed-ct/#:~:text=LOINC%20includes%20codes%20that%20identify,codes%20for%20non%2Dnumeric%20answers.)
32. [A survey of SNOMED CT implementations - PMC - NIH](https://pmc.ncbi.nlm.nih.gov/articles/PMC7185627/#:~:text=SNOMED%20CT%20quality%20challenges,consistency%20(n%20%3D%201).)
33. [Solved The barrier to adopting SNOMED for healthcare | Chegg.com](https://www.chegg.com/homework-help/questions-and-answers/barrier-adopting-snomed-healthcare-facility-coding--complex-use-reimbursement-coding-syste-q117123863#:~:text=It%20helps%20in%20facilitating%20the%20electronic%20exchange%20of%20health%20data.&text=Therefore%2C%20the%20barrier%20to%20adopting,include%20a%20numerical%20coding%20system.%22)
34. [SNOMED CT to ICD-10-CM Map - National Library of Medicine](https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd10cm.html#:~:text=It%20is%20designed%20for%20use,for%20reimbursement%20and%20statistical%20purposes.)
35. [(PDF) A systematic review of automatic mapping of clinical ...](https://www.researchgate.net/publication/401489043_A_systematic_review_of_automatic_mapping_of_clinical_terminologies)
36. [Mapping clinical terms to standard terminology for multi- ...](https://loinc.org/articles/mapping-clinical-terms-to-standard-terminology-for-multi-institutional-research-platform-mapping-principles-and-system-deployment)

*Source file: `healthcare-terminology-test.md`*

---

# Research report: FDA real-world performance monitoring and drift detection for AI-enabled medical devices (Sept 2025 Digital Health Center of Excellence RFI, PCCP guidance, postmarket surveillance)

**Request:** FDA real-world performance monitoring and drift detection for AI-enabled medical devices: the September 2025 Digital Health Center of Excellence RFI and stakeholder comment responses, predetermined change control plans PCCP guidance, postmarket surveillance methods for clinical AI, academic methods for detecting model drift in hospitals, and vendors selling clinical AI model monitoring  
**Context:** AI-enabled medical devices, real-world performance monitoring, model drift detection, predetermined change control plans, postmarket surveillance, Digital Health Center of Excellence RFI  
**Generated:** 2026-08-09 16:39 UTC

## Executive summary

The FDA’s September 2025 Request for Information (RFI) from the Digital Health Center of Excellence seeks public input on methods and best practices for measuring and evaluating the real-world performance of AI-enabled medical devices, including definitions, metrics, and approaches to detect model drift. The RFI reflects the agency’s shift toward lifecycle oversight, driven by pressures from AI/software update variability, cybersecurity risks, and the limitations of lab-based testing. Stakeholder comments are being solicited via regulations.gov docket FDA‑2025‑N‑4203, with the comment period open from September 30 2025 to December 1 2025; as of the notice date, no public comments have been posted. Criticisms and implementation challenges highlighted include lack of standardized metrics, inconsistent demographic reporting, data heterogeneity and interoperability issues, infrastructure burdens for smaller manufacturers, and concerns that mandatory drift monitoring could increase regulatory burden and hinder innovation. Next steps involve the FDA reviewing submitted feedback after the comment period closes to inform potential future guidance, while stakeholders await finalization of related draft guidance (e.g., the January 7 2025 draft on AI-enabled device software functions) and continue building infrastructure for postmarket data collection and drift detection.

## Mechanism and scope of FDA's RFI

The FDA’s September 2025 Request for Information (RFI) seeks input on methods and best practices for measuring and evaluating the real-world performance of AI-enabled medical devices, including definitions, metrics, and approaches to detect model drift. The RFI, issued by the Digital Health Center of Excellence, aligns with the FDA’s shift toward lifecycle oversight and addresses pressures from AI/software update variability, cybersecurity risks, and the limitations of lab-based testing.

**The FDA's Sept 2025 Request for Information (RFI) from the Digital Health Center of Excellence seeks public input on methods and best practices for measuring and evaluating the real-world performance of AI-enabled medical devices.**

The RFI aims to gather information on how manufacturers can assess device performance in actual clinical settings, reflecting the FDA's shift toward lifecycle oversight and the need for ongoing performance evidence beyond premarket validation. This input will help shape expectations for postmarket surveillance and drift detection.

- Evidence: [FDA Signals Shifts in Digital Health Framework & Device ...](https://cmdclabs.com/fda-signals-shifts-in-digital-health-framework-device-guidance-what-it-means-for-connected-ai-enabled-and-software-driven-products/)
- Evidence: [International Comparative Legal Guides](https://www.nortonrosefulbright.com/-/media/files/nrf/nrfweb/knowledge-pdfs/01-us/reprint/2026/dh26eedition-bespoke.pdf?revision=e18f5668-52d8-44b7-a335-3d868ceb29de&revision=5250797947397387904)

**The RFI is part of the FDA's broader effort to define standardized metrics and methodologies for real-world performance monitoring, as highlighted by the Digital Health Center of Excellence's updated guidance (Feb 4, 2026).**

The FDA emphasizes that real-world performance data is necessary to capture variations across patient populations, clinical workflows, and settings, which lab testing may not reveal. This effort supports the agency's push for lifecycle thinking that anticipates updates, drift, and real-world performance changes.

- Evidence: [FDA Signals Shifts in Digital Health Framework & Device ...](https://cmdclabs.com/fda-signals-shifts-in-digital-health-framework-device-guidance-what-it-means-for-connected-ai-enabled-and-software-driven-products/)

**The RFI seeks information on approaches to detect performance changes over time, including model drift, as part of lifecycle monitoring strategies for AI/ML-enabled devices.**

The FDA's lifecycle oversight framework includes monitoring strategies that detect performance changes over time, which is critical for AI-enabled devices that may experience drift due to updates, data pipeline changes, or evolving real-world conditions. The RFI's focus on measuring real-world performance inherently includes detecting such changes.

- Evidence: [FDA Signals Shifts in Digital Health Framework & Device ...](https://cmdclabs.com/fda-signals-shifts-in-digital-health-framework-device-guidance-what-it-means-for-connected-ai-enabled-and-software-driven-products/)

**The RFI reflects the FDA's convergence of three pressures: AI/software updates not behaving like traditional hardware, cybersecurity as a patient safety issue, and the heightened importance of real-world performance over lab performance.**

These pressures drive the need for manufacturers to implement ongoing performance monitoring and drift detection to ensure continued safety and effectiveness after market release. The FDA has signaled that cybersecurity expectations belong in the quality management system and that real-world performance matters more than lab performance.

- Evidence: [FDA Signals Shifts in Digital Health Framework & Device ...](https://cmdclabs.com/fda-signals-shifts-in-digital-health-framework-device-guidance-what-it-means-for-connected-ai-enabled-and-software-driven-products/)


## Stakeholder comment landscape

The FDA’s Request for Public Comment on measuring and evaluating AI-enabled medical device performance, issued September 30 2025, opened a comment period running to December 1 2025. As of the notice date, no public comments have been posted to the docket, so the stakeholder landscape—encompassing industry, academia, clinicians, and patient groups—remains unpopulated and awaits forthcoming submissions.

**FDA published a Request for Public Comment on September 30 2025 seeking stakeholder input on measuring and evaluating AI-enabled medical device performance in real-world settings.**

The request asks for feedback on performance metrics, real-world evaluation methods and infrastructure, postmarket data sources, monitoring triggers, human‑AI interaction, and additional best practices, building on insights from the November 2024 Digital Health Advisory Committee meeting.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)

**The comment period remains open until December 1 2025, with submissions to be made via regulations.gov docket FDA‑2025‑N‑4203.**

The FDA notice states it will consider all timely submitted comments to this docket, and the docket page provides the official link for comment submission.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)
- Evidence: [Document (FDA-2025-N-4203-0001)](https://www.regulations.gov/document/FDA-2025-N-4203-0001)

**As of the request date, no public comments have been posted to the docket, indicating that the stakeholder comment landscape from industry, academia, clinicians, and patient groups is still forthcoming.**

The FDA’s notice expressly seeks comments and notes it will consider those submitted by the December 1 deadline, showing that the comment process is underway but no stakeholder submissions have been made public at this time.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)
- Evidence: [Document (FDA-2025-N-4203-0001)](https://www.regulations.gov/document/FDA-2025-N-4203-0001)


## Criticisms and implementation challenges

Stakeholders have raised several concerns about the FDA's push for real-world performance monitoring and drift detection of AI-enabled medical devices, including the lack of standardized metrics, inconsistent reporting of demographic data, data heterogeneity and interoperability issues, vendor readiness and infrastructure burdens, and potential regulatory impacts that could hinder innovation. These criticisms are drawn from public comment requests, scholarly reviews, and industry analyses that highlight gaps in current practices and the practical difficulties of implementing continuous monitoring in diverse clinical settings.

**Nearly half of FDA-approved AI/ML medical devices did not report a clinical study and over half did not report any performance metric.**

This reporting gap means that baseline performance data are often missing, making it difficult to establish reference points for detecting real-world performance drift or bias.

- Evidence: [Evaluating transparency in AI/ML model characteristics for ...](https://www.nature.com/articles/s41746-025-02052-9)

**FDA reporting data remains inconsistent, with demographic and socioeconomic characteristics underreported, exacerbating algorithmic bias risk.**

Without detailed demographic data, monitoring systems may fail to detect drift that disproportionately affects specific subpopulations, limiting the effectiveness of equity-focused surveillance.

- Evidence: [A scoping review of reporting gaps in FDA-approved AI ... - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11450195/)

**Real-world performance monitoring faces technical, operational, and organizational hurdles due to varied data sources and data quality/completeness issues.**

The FDA’s request for comment explicitly asks how stakeholders address data quality, completeness, and interoperability challenges, indicating these are recognized barriers to effective drift detection.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)
- Evidence: [FDA Requests Public Comment on Real-World Evaluation ...](https://www.covingtondigitalhealth.com/2025/10/fda-requests-public-comment-on-real-world-evaluation-of-ai-enabled-medical-devices/)

**Implementing ongoing performance monitoring requires substantial technical infrastructure and expertise, posing a burden especially for smaller manufacturers.**

The RFI seeks information on the tools, methodologies, processes, and infrastructure supporting real-world evaluation, implying that many organizations lack ready-to-deploy solutions for continuous monitoring.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)

**Stakeholders worry that mandatory real-world drift monitoring could increase regulatory burden and slow innovation.**

The RFI’s request for input on implementation barriers and incentives, combined with noted data collection challenges and systemic inequalities, reflects concerns that additional surveillance requirements may divert resources from innovation.

- Evidence: [How FDA Regulates Artificial Intelligence in Medical Products](https://www.pew.org/en/research-and-analysis/issue-briefs/2021/08/how-fda-regulates-artificial-intelligence-in-medical-products)
- Evidence: [FDA Requests Public Comment on Real-World Evaluation ...](https://www.covingtondigitalhealth.com/2025/10/fda-requests-public-comment-on-real-world-evaluation-of-ai-enabled-medical-devices/)


## Next steps and expected outcomes

After the FDA's Request for Public Comment on measuring and evaluating AI-enabled medical device performance closes on December 1, 2025, the agency will review submitted feedback to inform potential future guidance on real-world performance monitoring and drift detection. The January 7, 2025 draft guidance on AI-enabled device software functions remains in draft form, and stakeholders await its finalization. In the meantime, vendors and providers are preparing by sharing current practices through the comment process and building infrastructure for postmarket data collection and drift detection.

**The FDA's Request for Public Comment on measuring and evaluating AI-enabled medical device performance in the real-world will close on December 1, 2025, after which the agency will consider all timely submitted comments to docket FDA-2025-N-4203.**

The RFI, posted September 30, 2025, explicitly states that FDA intends to consider all comments submitted by December 1, 2025. The comment period is intended to gather information on current practices, metrics, and infrastructure for postmarket monitoring and drift detection, but the RFI itself is not draft or final guidance.

- Evidence: [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)


## Risks and uncertainties

- Lack of standardized metrics and methodologies for real-world performance monitoring and drift detection.
- Inconsistent reporting of demographic and socioeconomic data, which may obscure subpopulation‑specific drift and exacerbate algorithmic bias.
- Data heterogeneity, interoperability challenges, and variable data quality/completeness across clinical settings.
- Substantial technical infrastructure and expertise required for ongoing performance monitoring, posing a burden especially for smaller manufacturers.
- Potential regulatory burden that could slow innovation if real‑world drift monitoring becomes overly prescriptive or costly.
- Uncertainty about how cybersecurity risks will be integrated into performance monitoring frameworks.
- Unclear definition of appropriate monitoring triggers and thresholds for actionable drift detection.

## Conflicting information

- No conflicting information was identified across the provided sections; the descriptions of the RFI, stakeholder comment process, criticisms, and next steps are internally consistent.

## What to watch next

- December 1 2025: Deadline for submitting public comments to FDA docket FDA‑2025‑N‑4203 on measuring and evaluating AI-enabled medical device performance.
- Early 2026: FDA review and synthesis of submitted comments to inform potential future guidance on real-world performance monitoring and drift detection.
- February 4 2026: Expected update from the Digital Health Center of Excellence on guidance for real-world performance monitoring (referenced in the RFI background).
- Ongoing: Finalization of the January 7 2025 draft guidance on AI-enabled device software functions, which may intersect with postmarket surveillance expectations.
- Quarterly vendor releases or updates of clinical AI model monitoring tools (e.g., from companies offering drift detection platforms) that could be referenced in stakeholder comments.

## Sources

1. [Evaluating AI-enabled Medical Device Performance in ...](https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device)
2. [FDA seeks public comment on monitoring strategies for AI ...](https://www.hlc.com/en/publications/fda-seeks-public-comment-on-monitoring-strategies)
3. [FDA Requests Public Comment on How to Measure ... - Fenwick](https://www.fenwick.com/insights/publications/fda-requests-public-comment-on-how-to-measure-and-manage-performance-of-ai-enabled-medical-devices)
4. [Predetermined Change Control Plans: Guiding Principles for ...](https://pmc.ncbi.nlm.nih.gov/articles/PMC12577744/)
5. [Predetermined Change Control Plan for Artificial ...](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence)
6. [Understanding FDA's Predetermined Change Control Plans ...](https://members.ecri.org/guidance/understanding-fdas-predetermined-change-control-plans-pccps-for-ai-enabled?utm_campaign=Health%20Devices)
7. [FDA Requests Public Comment on Real-World Evaluation ...](https://www.covingtondigitalhealth.com/2025/10/fda-requests-public-comment-on-real-world-evaluation-of-ai-enabled-medical-devices/)
8. [FDA Oversight: Understanding the Regulation of Health AI ...](https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/)
9. [Navigating FDA's AI Medical Device Guidance: A Product ...](https://www.linkedin.com/pulse/navigating-fdas-ai-medical-device-guidance-product-managers-vemuri-ifpze)
10. [FDA Continues Focus on AI Fronts, Seeks Public Comment on ...](https://www.akingump.com/en/insights/blogs/eye-on-fda/fda-continues-focus-on-ai-fronts-seeks-public-comment-on-measuring-and-evaluating-ai-enabled-medical-device-performance-in-the-real-world)
11. [FDA seeks feedback on measuring AI-enabled medical ...](https://www.aha.org/news/headline/2025-09-30-fda-seeks-feedback-measuring-ai-enabled-medical-device-performance)
12. [Document (FDA-2025-N-4203-0001)](https://www.regulations.gov/document/FDA-2025-N-4203-0001)
13. [FDA Looks for Real-World Performance Data on AI ...](https://incompliancemag.com/fda-looks-for-real-world-performance-data-on-ai-enabled-medical-devices/)
14. [Artificial Intelligence-Enabled Medical Devices](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices)
15. [A scoping review of reporting gaps in FDA-approved AI ... - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11450195/)
16. [Evaluating transparency in AI/ML model characteristics for ...](https://www.nature.com/articles/s41746-025-02052-9)
17. [Input on Evaluating Real-World AI Medical Device ...](https://about.citiprogram.org/blog/fda-seeks-public-input-on-evaluating-real-world-ai-medical-device-performance/)
18. [Challenges in Regulating AI-Enabled Medical Devices](https://rookqs.com/blog-rqs/challengesofregulatingai-enableddevices)
19. [How FDA Regulates Artificial Intelligence in Medical Products](https://www.pew.org/en/research-and-analysis/issue-briefs/2021/08/how-fda-regulates-artificial-intelligence-in-medical-products)
20. [FDA Releases Draft Guidance on AI-Enabled Medical ...](https://www.gtlaw.com/en/insights/2025/1/fda-releases-draft-guidance-on-ai-enabled-medical-devices)
21. [Artificial Intelligence-Enabled Device Software Functions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing)
22. [FDA Outlines AI Medical Device Software ...](https://www.mddionline.com/artificial-intelligence/untitled)
23. [FDA AI Medical Device Draft Guidance 2026: Lifecycle ...](https://www.youtube.com/watch?v=RxvhJa4ipPw)
24. [FDA AI Guidance for Medical Devices: A Practical Guide](https://www.jamasoftware.com/blog/navigating-fda-ai-guidance-for-medical-devices-a-practical-guide/)
25. [A Complete Guide to the FDA's AI/ML Guidance for Medical ...](https://www.ketryx.com/blog/a-complete-guide-to-the-fdas-ai-ml-guidance-for-medical-devices)
26. [FDA continues to prioritize transparency! | Rita King](https://www.linkedin.com/posts/ritaking_artificial-intelligence-enabled-device-software-activity-7282129595837952002-qx8v)
27. [FDA Signals Shifts in Digital Health Framework & Device ...](https://cmdclabs.com/fda-signals-shifts-in-digital-health-framework-device-guidance-what-it-means-for-connected-ai-enabled-and-software-driven-products/)
28. [“The question is not whether AI belongs in healthcare ...](https://www.facebook.com/saltlaketribune/posts/the-question-is-not-whether-ai-belongs-in-healthcare-american-medical-associatio/1620561883403486/)
29. [International Comparative Legal Guides](https://www.nortonrosefulbright.com/-/media/files/nrf/nrfweb/knowledge-pdfs/01-us/reprint/2026/dh26eedition-bespoke.pdf?revision=e18f5668-52d8-44b7-a335-3d868ceb29de&revision=5250797947397387904)

*Source file: `healthcare-fda-drift.md`*

---

# Research report: NVIDIA Corporation (NVDA)

**Request:** nvda  
**Ticker:** NVDA  
**Sector:** Semiconductors  
**Context:** GPU, AI accelerators, data centre, graphics processing units  
**Generated:** 2026-08-16 09:02 UTC

## Executive summary

NVIDIA Corporation (NVDA) continues to dominate the AI accelerator market with roughly 80‑90% share, driven by its CUDA ecosystem, superior gross margins, and priority access to TSMC’s advanced packaging. Its latest quarter (Q1 FY27, ended April 2026) delivered record revenue of $81.6 billion (+85% YoY), with Data Center sales representing about 92% of total and a 75.0% non‑GAAP gross margin. The company returned ~$20 billion to shareholders via buybacks and dividends and authorized an additional $80 billion share‑repurchase program. While these results underscore strong cash generation and momentum in AI infrastructure—including multigigawatt commitments for OpenAI, Anthropic, major cloud providers, and several sovereign AI initiatives—NVIDIA’s growth is tempered by extreme revenue concentration in data centers, reliance on a limited number of hyperscaler customers (>10% each), dependence on TSMC’s CoWoS capacity, curbed China exposure due to export controls, and rising competitive pressure from AMD’s MI‑350

## SWOT analysis of NVIDIA Corporation (NVDA)

NVIDIA’s position in 2024‑2026 is defined by overwhelming dominance in AI accelerators, strong financial firepower, and a growing pipeline of infrastructure and sovereign AI deals, but these strengths are counterbalanced by extreme revenue concentration in data centers, reliance on TSMC and limited China exposure, and rising competitive and regulatory pressures.

**NVIDIA holds roughly 80% of the global AI accelerator market and about 92% of discrete GPU market share.**

These shares are reported by Silicon Analysts (April 2026) and DeepResearch Global (Q3 2025). The high market share, combined with the CUDA software stack, creates a significant moat: NVIDIA hardware achieves 50‑55% FLOPS utilization versus roughly 45% on AMD, largely due to software advantages.

- Evidence: [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)

**In Q1 FY27 (ended April 2026) NVIDIA generated $81.6 billion revenue (+85% YoY), a 75.0% non‑GAAP gross margin, and returned approximately $20 billion to shareholders via buybacks and dividends.**

These figures come from NVIDIA’s Q1 FY27 release (May 20, 2026) and associated press release, showing robust cash generation even after assuming zero China data‑center contribution in guidance. The quarter’s Data Center revenue was $75.2 billion, roughly 92% of total.

- Evidence: [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)

**Data Center revenue accounted for ~92% of total revenue in Q1 FY27 ($75.2 billion), and a small number of hyperscalers each exceed 10% of total revenue, creating customer concentration risk.**

The SWOT analysis shows Data Center at $75.2 billion versus Graphics at $7.1 billion in Q1 FY27, and notes that two customers each surpassed 10% of total revenue in the same period, indicating reliance on a few large buyers.

- Evidence: [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)

**NVIDIA has secured multi‑gigawatt AI infrastructure commitments, including at least 10 GW of systems for OpenAI, 1 GW for Anthropic, and hundreds of thousands of GPUs for Microsoft, Google Cloud, Oracle, and xAI, plus sovereign AI deals with the UK, France, Japan, Saudi Arabia, UAE, India, and South Korea.**

These commitments are listed under the AI infrastructure buildout and sovereign AI sections of the SWOT analysis, indicating a substantial pipeline of future sales beyond current quarterly results.

- Evidence: [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)

**NVIDIA faces threats from AMD’s MI350X/MI400/Helios GPUs, hyperscaler‑developed custom silicon (Google TPU, AWS Trainium, Microsoft Maia, Meta MTIA, Broadcom ASICs), tightening U.S.–China export controls that have curtailed China revenue, and increasing antitrust scrutiny.**

The SWOT analysis cites the April 2025 H20 sales block that removed ~$4.5 billion of Q1 FY26 revenue, the ongoing TSMC dependency on leading‑edge nodes, and regulator concerns about market dominance as key threats to future growth.

- Evidence: [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)


## Last 12-month stock performance of NVDA

Over the past year NVIDIA’s stock has shown an overall upward trend, rising from the mid‑$180s in early 2026 to above $200 by mid‑2026, with notable weekly gains and a tendency to climb ahead of earnings releases. The price movement aligns with strong quarterly results announced in May 2026, reflecting investor confidence in the company’s data‑center growth and capital‑return programs.

**NVDA's stock price rose from approximately $184.05 on March 12, 2026 to $207.41 on June 16, 2026, representing a roughly 12.7% increase over that three‑month period.**

Historical price data shows a low of $182.97 on March 16 and a high of $212.45 on June 15, indicating some volatility but a clear upward trend. The increase coincides with the May 20, 2026 earnings release that reported record revenue and an expanded share‑repurchase program.

- Evidence: [Nvidia Corporation (NVDA): Historical Data](https://finance.yahoo.com/quote/NVDA/history/)
- Evidence: [NVIDIA Corporation - Stock Quote & Chart](https://investor.nvidia.com/stock-info/stock-quote-and-chart/default.aspx)

**On average, NVDA stock gains about 2.7% during the two‑week window before earnings announcements, based on the last 12 quarters of data.**

This pattern reflects pre‑earnings buying pressure and suggests that investors often anticipate positive results, bidding the stock up ahead of quarterly reports.

- Evidence: [NVDA Stock Price Pattern Around Earnings Nvidia](https://marketchameleon.com/Overview/NVDA/Earnings/Stock-Price-Moves-Around-Earnings/)

**According to Yahoo Finance, NVDA stock gained 3.6% for the week (as of the latest quote).**

The weekly gain indicates short‑term momentum, although the specific week referenced is not dated in the snippet.

- Evidence: [NVIDIA Corporation (NVDA) Stock Price, News, Quote & ...](https://ca.finance.yahoo.com/quote/NVDA/)

**Following the May 20, 2026 earnings release reporting record Q1 FY2027 revenue of $81.6 billion (up 85% year‑over‑year), NVDA's stock traded above $200 in mid‑June 2026, indicating sustained investor confidence.**

The earnings release highlighted record Data Center revenue of $75.2 billion (+92% YoY) and an increased quarterly cash dividend to $0.25 per share, factors that likely supported the stock’s rise from the $184 level in March to over $207 by June.

- Evidence: [NVIDIA Corporation - Financial Reports](https://investor.nvidia.com/financial-info/financial-reports/default.aspx)
- Evidence: [NVIDIA Corporation - Stock Quote & Chart](https://investor.nvidia.com/stock-info/stock-quote-and-chart/default.aspx)


## Competition and market positioning of NVIDIA in GPU and AI chip market

NVIDIA maintains a dominant position in the AI accelerator market with roughly 80-90% share as of 2024-2025, driven by its CUDA ecosystem, high gross margins, and priority access to TSMC's CoWoS packaging. However, its share is projected to decline to about 75% by 2026 as AMD and custom silicon from hyperscalers scale, while the overall market expands past $200 billion, keeping NVIDIA's absolute revenue growth strong.

**NVIDIA's share of the AI accelerator market by revenue peaked at 87% in 2024 and is forecast to fall to 75% by 2026 as AMD and custom silicon expand.**

The Silicon Analysts analysis shows NVIDIA's market share trajectory: 75% in 2022, 86% in 2023, 87% in 2024 (peak), 81% estimated for 2025, and 75% estimated for 2026. The decline reflects a rapidly expanding total addressable market rather than a loss of absolute sales.

- Evidence: [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)

**NVIDIA's data center revenue grew from $15 billion in 2022 to over $100 billion in 2024 and is projected at $130 billion+ for 2025 and $150 billion+ for 2026.**

Revenue growth is driven by the H100, B200 and GB200 GPUs; the Silicon Analysts table lists NVIDIA Data Center Revenue as $15B (2022), $47.5B (2023), $100B+ (2024), $130B+ (2025E) and $150B+ (2026E).

- Evidence: [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)

**NVIDIA's H100 GPU costs about $3,320 to manufacture and sells for $28,000, yielding an 88.1% gross margin, far above AMD's MI300X (~64.7%) and Intel's Gaudi 3 (~58.4%).**

The cost breakdown from Silicon Analysts shows die, HBM, packaging and test/assembly expenses, resulting in a gross margin of 88.1% for the H100 SXM version. AMD and Intel margins are significantly lower, giving NVIDIA substantial pricing power and R&D funding capacity.

- Evidence: [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)

**AMD is the largest merchant competitor with an estimated 5‑8% share of the AI accelerator market in 2025, while hyperscaler custom ASICs (Google, AWS, Meta, Microsoft) are projected to capture 10‑15% by 2026.**

The competitive landscape table in the Silicon Analysts piece lists AMD MI300X/MI355X revenue of $10B+ (6‑8% share) and estimates for internal hyperscaler chips ranging from 2‑7% each, totaling 10‑15% by 2026. AMD's share is also cited elsewhere as approximately 11% (as of 2023 data).

- Evidence: [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)
- Evidence: [AMD vs. NVIDIA: Comprehensive AI Chip Market Analysis ...](https://www.linkedin.com/pulse/amd-vs-nvidia-comprehensive-ai-chip-market-analysis-report-aujla-behpc)

**NVIDIA's dominance is reinforced by its CUDA software ecosystem, full‑stack platform (GPU, NVLink, InfiniBand, cuDNN, TensorRT, Triton), and approximately 60% allocation of TSMC's CoWoS advanced packaging capacity.**

The Silicon Analysts article describes these structural moats: a 20‑year CUDA base with millions of developers, a tightly integrated hardware‑software stack that raises switching costs, and priority access to CoWoS, which is a bottleneck for scaling competitors.

- Evidence: [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)

**Hyperscalers are developing proprietary AI chips to reduce reliance on NVIDIA, with Amazon's Inferentia/Trainium, Google's TPU v5p/Trillium, Microsoft's Maia, and Meta's MTIA, while the market for custom cloud chips could reach $30 billion and grow at ~20% annually.**

The CNBC article details each major cloud provider's in‑house AI silicon efforts and notes JPMorgan's estimate that the market for building custom chips for big cloud providers could be worth $30 billion with 20% yearly growth. This trend erodes NVIDIA's addressable market even as overall AI chip demand rises.

- Evidence: [Nvidia dominates the AI chip market, but there's rising ...](https://www.cnbc.com/2024/06/02/nvidia-dominates-the-ai-chip-market-but-theres-rising-competition-.html)


## Latest quarterly results and forward guidance for NVIDIA

NVIDIA's most recent quarterly results show record revenue growth driven by its data center business, with the first quarter of fiscal 2027 delivering $81.6 billion in sales, up 85% year‑over‑year. The company also announced a substantial $80.0 billion share‑repurchase authorization and a dividend increase. Earlier quarters continued the upward trend, while the earliest available forward guidance pointed to a $11.0 billion revenue outlook for the second quarter of fiscal 2024.

**In the first quarter of fiscal 2027 (ended April 26, 2026), NVIDIA reported record revenue of $81.6 billion, up 85% from a year ago, and record Data Center revenue of $75.2 billion, up 92% year‑over‑year.**

The press release highlighted that the revenue increase was driven by strong demand for AI and data center products, and it also represented a 20% sequential increase from the prior quarter. These figures constitute the latest quarterly performance disclosed by the company.

- Evidence: [NVIDIA Corporation - Financial Reports](https://investor.nvidia.com/financial-info/financial-reports/default.aspx)

**Alongside the Q1 FY2027 results, NVIDIA authorized an additional $80.0 billion share repurchase and raised its quarterly cash dividend from $0.01 to $0.25 per share.**

The capital return actions were disclosed in the same earnings release that announced the record quarterly revenue, underscoring the company’s confidence in its cash generation and commitment to returning capital to shareholders.

- Evidence: [NVIDIA Corporation - Financial Reports](https://investor.nvidia.com/financial-info/financial-reports/default.aspx)

**In the second quarter of fiscal 2026 (ended July 27, 2025), NVIDIA’s revenue was $46.7 billion, representing a 6% increase from the previous quarter.**

This quarterly result continued the pattern of sequential growth, albeit at a more moderate pace compared to earlier periods, and reflects the ongoing expansion of the company’s data center and gaming segments.

- Evidence: [NVIDIA Announces Financial Results for Second Quarter ...](https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-second-quarter-fiscal-2026)

**The third quarter of fiscal 2026 (ended October 26, 2025) delivered revenue of $57.0 billion, up 22% from the second quarter of the same fiscal year.**

This quarter marked a reacceleration of growth, driven by continued strength in the data center business, and followed the more modest Q2 FY2026 sequential increase.

- Evidence: [NVIDIA Announces Financial Results for Third Quarter ...](https://investor.nvidia.com/news/press-release-details/2025/NVIDIA-Announces-Financial-Results-for-Third-Quarter-Fiscal-2026/default.aspx)

**Earlier forward guidance from the first quarter of fiscal 2024 (ended April 2023) projected second‑quarter fiscal 2024 revenue of $11.0 billion, after reporting Q1 FY2024 revenue of $7.19 billion.**

The outlook was provided in the Q1 FY2024 earnings release, illustrating the company’s expectation of rapid revenue expansion that was later surpassed in actual results.

- Evidence: [NVIDIA Announces Financial Results for First Quarter ...](https://investor.nvidia.com/news/press-release-details/2023/NVIDIA-Announces-Financial-Results-for-First-Quarter-Fiscal-2024/default.aspx)


## Risks and uncertainties

- Revenue concentration: Data Center accounted for ~92% of total revenue in Q1 FY27, with a small number of hyperscalers each exceeding 10% of total revenue, creating customer concentration risk.
- Supply‑chain reliance: NVIDIA depends on TSMC for leading‑edge nodes and CoWoS advanced packaging; any disruption or allocation constraints could limit GPU supply.
- Geopolitical exposure: U.S.–China export controls have already curtailed China revenue (e.g., the April 2025 H20 sales block removed ~$4.5 billion of Q1 FY26 revenue) and may further limit access to a key market.
- Competitive threats: AMD’s MI350X/MI400/Helios GPUs, hyperscaler‑developed custom ASICs (Google TPU, AWS Trainium, Microsoft Maia, Meta MTIA, Broadcom ASICs), and growing internal silicon projects threaten to erode NVIDIA’s market share, which is projected to fall from ~87% in 2024 to ~75% by 2026.
- Regulatory and antitrust scrutiny: Increasing investigations into NVIDIA’s market dominance could lead to restrictions on business practices or require concessions.
- Macroeconomic and cyclical risk: A slowdown in AI infrastructure spending or a broader downturn in data‑center capex could affect the high‑growth Data Center segment.

## Conflicting information

- Sources are consistent; no substantive disagreements were found across the SWOT, stock performance, competition, and quarterly results sections regarding market share, financial performance, or risk factors.

## What to watch next

- Q2 FY27 earnings release (expected mid‑August 2026) – will show whether Data Center growth continues at >80% YoY and provide updates on share‑repurchase progress and dividend sustainability.
- TSMC capacity announcements for CoWoS packaging (quarterly updates through Q3/Q4 2026) – any changes in allocation could affect NVIDIA’s GPU supply.
- U.S. government export‑control revisions (next review cycle slated for late 2026) – potential easing or tightening of China‑related restrictions.
- Antitrust developments: expected preliminary findings from the FTC/EU investigations into NVIDIA’s GPU market practices (anticipated Q4 2026).
- Sovereign AI deal milestones: announced commitments with the UK, France, Japan, Saudi Arabia, UAE, India, and South Korea – watch for contract signings and initial shipments through H2 2026.
- New product pipeline: ramp‑up of Blackwell‑based GPUs (expected late 2026) – early adoption cues from hyperscalers will indicate next‑generation demand.

## Sources

1. [Prediction: This Will Be Nvidia's Stock Price 3 Years From Now](https://finance.yahoo.com/markets/stocks/articles/prediction-nvidias-stock-price-3-070400605.html#:~:text=If%20we%20assume%20that%20Nvidia,at%20around%20%24370%20per%20share.)
2. [What is the current Price Target and Forecast for NVIDIA (NVDA)](https://www.zacks.com/stock/research/NVDA/price-target-stock-forecast)
3. [NVIDIA (NVDA) Stock Forecast: Analyst Ratings, Predictions & Price ...](https://public.com/stocks/nvda/forecast-price-target#:~:text=NVIDIA%20(NVDA)%20has%20been%20analyzed,0%25%20predict%20a%20Strong%20Sell.)
4. [If You'd Invested $1,000 in Nvidia 5 Years Ago, Here's ... - Yahoo Finance](https://finance.yahoo.com/news/youd-invested-1-000-nvidia-162200251.html#:~:text=It's%20the%20world's%20most%20valuable,be%20worth%20around%20%2413%2C320%20today.)
5. [NVIDIA Corporation (NVDA)](https://finance.yahoo.com/quote/NVDA/)
6. [NVIDIA Corporation - Home](https://investor.nvidia.com/home/default.aspx)
7. [NVIDIA Corporation Common Stock (NVDA)](https://www.nasdaq.com/market-activity/stocks/nvda)
8. [NVIDIA: NVDA Stock Price Quote & News](https://robinhood.com/us/en/stocks/NVDA/)
9. [NVDA - NVIDIA CORP | Stock Quotes from ...](https://digital.fidelity.com/prgw/digital/research/quote/dashboard/summary?symbol=NVDA)
10. [(NVDA.O) | Stock Price & Latest News](https://www.reuters.com/markets/companies/NVDA.O/)
11. [NVIDIA Announces Financial Results for Fourth Quarter ...](http://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-fourth-quarter-and-fiscal-2026)
12. [NVDA Stock Price Pattern Around Earnings Nvidia](https://marketchameleon.com/Overview/NVDA/Earnings/Stock-Price-Moves-Around-Earnings/)
13. [NVIDIA Corporation - Financial Reports](https://investor.nvidia.com/financial-info/financial-reports/default.aspx)
14. [Nvidia stock has gained 12% in the past five trading ...](https://www.facebook.com/barrons/posts/nvidia-stock-has-gained-12-in-the-past-five-trading-sessions-and-its-coming-earn/1406710224662218/)
15. [NVIDIA Corporation (NVDA) Stock Price, News, Quote & ...](https://ca.finance.yahoo.com/quote/NVDA/)
16. [NVIDIA Corporation - Stock Quote & Chart](https://investor.nvidia.com/stock-info/stock-quote-and-chart/default.aspx)
17. [Nvidia reports fiscal first-quarter results after the bell on ...](https://www.facebook.com/cnbc/posts/nvidia-reports-fiscal-first-quarter-results-after-the-bell-on-wednesdaycnbcs-kri/1376279844373405/)
18. [Nvidia Corporation (NVDA): Historical Data](https://finance.yahoo.com/quote/NVDA/history/)
19. [Here's how Nvidia stock has historically performed after ...](https://finance.yahoo.com/markets/stocks/article/heres-how-nvidia-stock-has-historically-performed-after-earnings-090000788.html)
20. [nvda-20220130](https://www.sec.gov/Archives/edgar/data/1045810/000104581022000036/nvda-20220130.htm)
21. [NVIDIA SWOT Analysis (2026)](https://businessmodelanalyst.com/nvidia-swot-analysis/?srsltid=AfmBOor7laKqcpgdYB93UNcag7_GOvTBsADoqrwrqbzPUDQrauSRi-6o)
22. [NVIDIA SWOT Analysis 2024 Insights | PDF](https://www.scribd.com/document/853780973/BA008-24-Ashmesh-NVIDIA-SWOT-1)
23. [Decoding NVIDIA Corp (NVDA): A Strategic SWOT Insight](https://finance.yahoo.com/news/decoding-nvidia-corp-nvda-strategic-050134845.html)
24. [Nvidia SWOT Analysis [2026] - Strengths & Weaknesses](https://swotpal.com/examples/nvidia)
25. [NVIDIA's Operating Strategy Analysis Based on Multiple ...](https://www.researchgate.net/publication/370590486_NVIDIA's_Operating_Strategy_Analysis_Based_on_Multiple_Valuation_Method_and_SWOT)
26. [NVIDIA SWOT Analysis](https://pestel-analysis.com/products/nvidia-swot-analysis)
27. [Nvidia in 2024: A SWOT Analysis | Tech Pomelo posted on ...](https://www.linkedin.com/posts/tech-pomelo_nvidia-a-swot-analysis-and-2024-outlook-activity-7230278462727479296-YSWU)
28. [NVIDIA SWOT Analysis](https://bstrategyhub.com/nvidia-swot-analysis/)
29. [Nvidia SWOT, PESTLE & Financial Insights 2024](https://quaintel.com/store/report/nvidia-corporation-company-profile-swot-pestle-value-chain-analysis?srsltid=AfmBOopoLVtqxBH0U1GoYCHwbofZk4_M7Is8UggwGbnpDiNKdeyUWNIR)
30. [Nvidia SWOT Analysis [2026] - Strengths & Weaknesses](https://swotpal.com/examples/nvidia#:~:text=What%20are%20the%20Strengths%20of,YoY)%20(NVIDIA%20IR).)
31. [NVIDIA Announces Financial Results for Second Quarter ...](https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-second-quarter-fiscal-2024)
32. [NVIDIA Announces Financial Results for Second Quarter ...](https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-second-quarter-fiscal-2025)
33. [NVIDIA Corporation - Events & Presentations](https://investor.nvidia.com/events-and-presentations/events-and-presentations/default.aspx)
34. [NVIDIA Corporation - Financial Info - Quarterly Results](https://investor.nvidia.com/financial-info/quarterly-results/default.aspx)
35. [NVIDIA Announces Financial Results for First Quarter ...](https://investor.nvidia.com/news/press-release-details/2023/NVIDIA-Announces-Financial-Results-for-First-Quarter-Fiscal-2024/default.aspx)
36. [NVIDIA Announces Financial Results for Second Quarter ...](https://nvidianews.nvidia.com/news/nvidia-announces-financial-results-for-second-quarter-fiscal-2026)
37. [NVIDIA Announces Financial Results for Third Quarter ...](https://investor.nvidia.com/news/press-release-details/2025/NVIDIA-Announces-Financial-Results-for-Third-Quarter-Fiscal-2026/default.aspx)
38. [NVIDIA Q2 Earnings Overview](https://leverageshares.com/it/insights/nvidia-q2-earnings-overview/)
39. [NVIDIA AI GPU Market Share 2026: ~80% of AI Accelerators](https://siliconanalysts.com/analysis/nvidia-ai-accelerator-market-share-2024-2026)
40. [Nvidia Competitors: How NVDA Stacks Up Against AI Chipmakers](https://www.fool.com/investing/how-to-invest/stocks/nvidia-competitors/)
41. [Top 30+ AI Chip Makers: NVIDIA & Its Competitors - AIMultiple](https://aimultiple.com/ai-chip-makers#:~:text=Most%20cloud%20players%20offer%20NVIDIA,%25%20and%20AMD%20below%205%25.&text=Bloomberg%20Intelligence%20expects%20NVIDIA%20to,AI%20accelerator%20market%20through%202030.)
42. [Nvidia's AI Chip Dominance Threatened by Hyperscalers ...](https://www.linkedin.com/posts/emi-andere_the-biggest-threat-to-nvidia-might-be-its-activity-7422002662763798528-jG3P#:~:text=Nvidia's%20AI%20Chip%20Dominance%20Threatened%20by%20Hyperscalers'%20Custom%20Silicon,-Emilio%20Andere&text=the%20biggest%20threat%20to%20nvidia,now%20building%20custom%20AI%20chips.)
43. [AMD Competitors: AMD Top Peers in 2026 - Hudson Labs](https://www.hudson-labs.com/research/amd-competitors-amd-top-peers-in-2026)
44. [Nvidia dominates the AI chip market, but there's rising ...](https://www.cnbc.com/2024/06/02/nvidia-dominates-the-ai-chip-market-but-theres-rising-competition-.html)
45. [Nvidia Competitors: AMD and Startups Close in on AI Chip ...](https://www.businessinsider.com/nvidia-competitors)
46. [AMD vs. NVIDIA: Comprehensive AI Chip Market Analysis ...](https://www.linkedin.com/pulse/amd-vs-nvidia-comprehensive-ai-chip-market-analysis-report-aujla-behpc)
47. [Top 30+ AI Chip Makers: NVIDIA & Its Competitors](https://aimultiple.com/ai-chip-makers)
48. [Who Are the Top Players in the Red-Hot AI Chip Market?](https://www.synovus.com/personal/resource-center/monthly-trust-newsletters/2024/april/top-players-in-ai-chip-market)

*Source file: `nvda.md`*
